Azaquinoline ring derivative

By developing novel azaquinoline ring derivative compounds, the shortcomings of existing Cot kinase inhibitors have been overcome, achieving highly efficient inhibition of Osaka thyroid cancer (Cot) kinase, which is suitable for the treatment of various Cot-mediated diseases such as rheumatoid arthritis and multiple sclerosis.

WO2024245157A1PCT designated stage expired Publication Date: 2024-12-05SHANGHAI FOSUN PHARMA DEV CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/095296
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing technologies lack Osaka thyroid cancer (Cot) kinase inhibitors with superior activity, better metabolic stability, and better safety, making them ineffective in treating Cot-mediated diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and other immune-related diseases.

Method used

A class of novel azaquinoline ring derivative compounds are provided as Cot kinase inhibitors, which achieve highly efficient inhibition of Cot through a combination of specific structural groups, including various pharmaceutically acceptable salts, tautomers, stereoisomers and isotopic substitutes.

Benefits of technology

This compound exhibits excellent Cot kinase inhibitory activity, specifically inhibiting Cot kinase, and can be used for the prevention or treatment of Cot-mediated diseases. It has a longer half-life and higher bioavailability, making it suitable for the preparation of related drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024095296_05122024_PF_FP_ABST
    Figure CN2024095296_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided in the present invention is an azaquinoline ring derivative. Specifically, provided in the present invention are a compound of formula I, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers or an isotope substitute thereof. The compound has excellent inhibitory activity on cancer Osaka thyroid (Cot) kinase, and thus can be used for preventing or treating diseases or conditions mediated by cancer Osaka thyroid (Cot) kinase.
Need to check novelty before this filing date? Find Prior Art

Description

Azaquinoline ring derivatives Technical Field

[0001] The present invention relates to a series of azaquinoline ring derivatives, and in particular to compounds represented by formula I and pharmaceutically acceptable salts thereof. Background Art

[0002] The Cot (Osaka thyroid carcinoma) protein is a serine / threonine kinase that is a member of the MAP kinase kinase kinase (MAP3K) family. It is also known as "TPL2" (tumor progression locus), "MAP3K8" (mitogen-activated protein kinase kinase kinase 8), or "EST" (Ewing sarcoma transformant). Cot was originally discovered as an oncogene in human thyroid cancer cell lines and has since been shown to play a crucial role in regulating inflammatory pathways.

[0003] Cot is located downstream of receptors such as TNF-αR, IL-1R, and TLRs, promoting the production and signaling of inflammatory factors such as TNF-α and IL-1β by activating the MEK-ERK pathway. TNF-α is a proinflammatory cytokine and plays a key role in immune-related diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), diabetes, sepsis, psoriasis, and transplant rejection. Cot can also promote the secretion of inflammatory mediators by neutrophils by activating p38α and p38δ.

[0004] Therefore, there is an urgent need in the art to provide new drugs with better activity, better metabolic stability and better safety that can inhibit diseases related to Cot activity.

[0005] Summary of the Invention

[0006] The present invention aims to provide a class of Osaka thyroid carcinoma (Cot) kinase inhibitor compounds with novel structure and excellent inhibitory activity, and also provides the use thereof in treating diseases or conditions mediated by Osaka thyroid carcinoma (Cot) kinase.

[0007] In a first aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitution thereof,

[0008] in

[0009] X 1 N or CR 15 ;

[0010] X 2 and X 3 are independently N or CH;

[0011] where X 1 、X2 and X 3 At least one is N;

[0012] R 1 For hydrogen, -OR 7 、-N(R 8 )(R 9 )、-C(O)-R 7 、-S(O)2-R 7 、C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 3-10 Heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 1 ;

[0013] R 2 is hydrogen, -C(O)-R 7 、-C(O)OR 7 、-C(O)N(R 7 )2、C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl may be optionally substituted with 1 to 4 Z 2 ;

[0014] or R 1 and R 2 Together with the nitrogen to which they are attached, they form a heterocyclic or heteroaryl group, wherein each heterocyclic or heteroaryl group is optionally substituted with 1 to 4 Z 2 ;

[0015] R 3 is ethynyl, heterocyclic or heteroaryl, wherein each ethynyl, heterocyclic or heteroaryl group optionally has 1 to 4 Z 3 ;

[0016] R 4 is a heterocyclic group, an aryl group or a heteroaryl group, wherein the heterocyclic group, the aryl group or the heteroaryl group is optionally substituted with 1 to 4 Z4 ;

[0017] R 5 For hydrogen, halogen, -CN, -NO2, -OR 7 、-N(R 8 )(R 9 ),-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2、-C(O)R 7 、-OC(O)-R 7 、-C(O)OR 7 、-OC(O)OR 7 、-OC(O)N(R 10 )(R 11 )、-C(O)N(R 7 )2、-N(R 7 )C(O)(R 7 ), C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl and heteroaryl groups may be optionally substituted with 1 to 4 Z 5 ;

[0018] R 6 is hydrogen, -C(O)-R 7 、-C(O)OR 7 、-C(O)N(R 7 )2、C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 3-10 Heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 6 ;

[0019] Each R 7 are independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl, or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl and heteroaryl groups may be optionally substituted with 1 to 4 Z 7 ;

[0020] R 8 and R 9 is independently hydrogen at each occurrence, -S(O)2-R 10 、-C(O)-R 10 、-C(O)OR 10 、-C(O)N(R 10 )(R 11) 、C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 8 ;

[0021] R 10 and R 11 is independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 9 ;

[0022] Every Z 1 、Z 2 、Z3 、Z 4 、Z 5 、Z 6 、Z 7 、Z 8 and Z 9 are independently hydrogen, oxo, halogen, -NO2, -N3, -CN, thio, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-8 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl, -OR 12 、-C(O)R 12 、-C(O)OR 12 、-C(O)N(R 13 )(R 14 )、-N(R 13 )(R 14 )、-N(R 13 )2(R 14 ) + 、-N(R 12 )C(O)-R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 13 )(R 14 )、-N(R 12 )S(O)2(R 12 ),-NR 12 S(O)2N(R 13 )(R 14 ),-NR 12 S(O)2O(R 12 ),-OC(O)R 12 、-OC(O)-N(R 13 )(R 14 )、-P(O)(OR 12 )2、-OP(O)(OR 12 )2、-CH2P(O)(OR 12 )2、-OCH2P(O)(OR 12 )2、-C(O)OCH2P(O)(OR 12 )2、-P(O)(R 12 )(OR 12 ),-OP(O)(R 12 )(OR 12 )、-CH2P(O)(R 12 )(OR 12)、-OCH2P(O)(R 12 )(OR 12 )、-C(O)OCH2P(O)(R 12 )(OR 12 )、-P(O)(N(R 12 )2)2、-OP(O)(N(R 12 )2)2、-CH2P(O)(N(R 12 )2)2、-OCH2P(O)(N(R 12 )2)2、-C(O)OCH2P(O)(N(R 12 )2)2、-P(O)(N(R 12 )2)(OR 12 )、-OP(O)(N(R 12 )2)(OR 12 )、-CH2P(O)(N(R 12 )2)(OR 12 )、-OCH2P(O)(N(R 12 )2)(OR 12 )、-C(O)OCH2P(O)(N(R 12 )2)(OR 12 )、-P(O)(R 12 )(N(R 12 )2)、-OP(O)(R 12 )(N(R 12 )2)、-CH2P(O)(R 12 )(N(R 12 )2)、-OCH2P(O)(R 12 )(N(R 12 )2)、-C(O)OCH2P(O)(R 12 )(N(R 12 )2),-SR 12 、-S(O)R 12 、-S(O)(NH)R 12 、-S(O)2R 12 Or -S(O)2N(R 13 )(R 14 ); wherein any alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, aryl, heteroaryl or heterocyclic radical is optionally selected from oxo, halogen, thio, hydroxyl, -NO2, -CN, -N3, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 1-9 Alkoxy, C 1-9 Alkyl hydroxyl, amino, C1-9 Alkylamino, (C 1-9 Alkyl)2amino, C 1-8 Halogenated alkyl, C 1-9 Alkylcarbonyl, C 1-9 Alkylamide, C 1-9 substituted by 1 to 4 substituents selected from alkylsulfonyl, aryl, heteroaryl, and heterocyclic groups;

[0023] Each R 12 are independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein any alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group optionally has 1 to 4 Z 7 group;

[0024] R 13 and R 14 Each occurrence is independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, aryl or heteroaryl; wherein any alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclic group optionally has 1 to 4 Z 8 group; or R 13 and R 14 Together with the nitrogen to which they are attached, they form a heterocyclic group, wherein the heterocyclic group is optionally substituted with 1 to 4 Z 8 group;

[0025] Each R 15 are independently halogen, -CN, -NO2, -OR 7 、-N(R 8 )(R 9 ),-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2、-C(O)R 7 、-OC(O)-R 7 、-C(O)OR 7 、-OC(O)OR 7 、-OC(O)N(R 10 )(R 11 )、-C(O)N(R 7 )2、-N(R 7 )C(O)(R 7 ), C 1-9 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Halogenated alkyl, C 3-15 cycloalkyl, aryl, heterocyclyl or heteroaryl;

[0026] m is 0, 1 or 2.

[0027] Every Z 1 、Z 2 、Z 3 、Z 4 、Z 5 、Z 6 、Z 7 、Z 8 and Z 9 are independently hydrogen, oxo, halogen, -NO2, -N3, -CN, thio, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-8 Halogenated alkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl, -OR 12 、-C(O)R 12 、-C(O)OR 12 、-C(O)N(R 13 )(R 14 )、-N(R 13 )(R 14 )、-N(R 13 )2(R 14 ) + 、-N(R 12 )C(O)-R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 13 )(R 14 )、-N(R 12 )S(O)2(R 12 ),-NR 12 S(O)2N(R 13 )(R 14 ),-NR 12 S(O)2O(R 12 ),-OC(O)R 12 、-OC(O)-N(R 13 )(R 14 )、-P(O)(OR 12 )2、-OP(O)(OR 12 )2、-CH2P(O)(OR12 ) 2, -OCH2P(O)(OR 12 ) 2, -C(O)OCH2P(O)(OR 12 ) 2, -P(O)(R 12 )(OR 12 )、-OP(O)(R 12 )(OR 12 )、-CH2P(O)(R 12 )(OR 12 )、-OCH2P(O)(R 12 )(OR 12 )、-C(O)OCH2P(O)(R 12 )(OR 12 )、-P(O)(N(R 12 )2)2、-OP(O)(N(R 12 )2)2、-CH2P(O)(N(R 12 )2)2、-OCH2P(O)(N(R 12 )2)2、-C(O)OCH2P(O)(N(R 12 )2)2、-P(O)(N(R 12 )2)(OR 12 )、-OP(O)(N(R 12 )2)(OR 12 )、-CH2P(O)(N(R 12 )2)(OR 12 )、-OCH2P(O)(N(R 12 )2)(OR 12 )、-C(O)OCH2P(O)(N(R 12 )2)(OR 12 )、-P(O)(R 12 )(N(R 12 )2)、-OP(O)(R 12 )(N(R 12 )2)、-CH2P(O)(R 12 )(N(R 12 )2)、-OCH2P(O)(R 12 )(N(R 12 )2)、-C(O)OCH2P(O)(R 12 )(N(R 12 )2)、-S-R<着 12 、-S(O)R 12 、-S(O)(NH)R 12 、-S(O)2R 12 或者 -S(O)2N(R 13 It should be noted that there may be some incorrect or unclear notations in the original text (such as "<着 12 "), and this translation is based on the best understanding of the existing content.)(R 14 ); wherein any alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, aryl, heteroaryl or heterocyclic group is optionally selected from oxo, halogen, thio, -NO2, -CN, -N3, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 1-9 Alkoxy, amino, C 1-9 Alkylamino, (C 1-9 Alkyl)2amino, C 1-8 Halogenated alkyl, C 1-9 Alkylcarbonyl, C 1-9 The alkylamide group is substituted by 1 to 4 substituents selected from the group consisting of alkylamide group, aryl group, heteroaryl group and heterocyclic group.

[0028] In another preferred embodiment, the compound of formula I has the structure shown in formula Ia:

[0029] where X 1 、X 2 、X 3 、R 1 -R 6 、R 15 and m as described herein.

[0030] In another preferred embodiment, the compound of formula I has the structure shown in formula Ib:

[0031] where X 1 、X 2 、X 3 、R 1 -R 6 、R 15 and m as described herein.

[0032] In another preferred embodiment, the compound of formula I is a mixture of formula Ia and formula Ib. Preferably, the proportion of formula Ia in the mixture is greater than 50%, more preferably, ≥75%, ≥80%, ≥85%, ≥90%, ≥95%, or even ≥98% or ≥99%.

[0033] In another preferred embodiment, wherein R 1 and R 2 There is only one hydrogen in it.

[0034] In another preferred embodiment, the compound has a structure shown in Formula II:

[0035] where X 1 、X 2 、X 3 、R1 、R 3 、R 4 、R 5 and R 6 As defined herein.

[0036] In another preferred embodiment, the compound has the structure shown in Formula IIa:

[0037] where X 1 、X 2 、X 3 、R 1 、R 3 、R 4 、R 5 and R 6 As defined herein.

[0038] In another preferred embodiment, R 2 For hydrogen.

[0039] In another preferred embodiment, R 1 Selected from C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 3-10 Heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -OH, -CN, -OR 12 、C 1-9 Alkyl and aryl groups.

[0040] In another preferred embodiment, R 1 Selected from C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclyl, C6 aryl or 5-7 membered heteroaryl, wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclyl, C6 aryl or 5-7 membered heteroaryl may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -OH, -CN, -OR 12 、C 1-9 Alkyl and C6 aryl.

[0041] In another preferred embodiment, R1 Select from the following groups:

[0042] In another preferred embodiment, R 1 for or R 1 、R 2 With the connected N atom to form and

[0043] In Formula I, -(R 15 )m represents the six-membered ring connected thereto has m R 15 group.

[0044] In another preferred embodiment, X 1 、X 2 and X 3 are independently N or CR 15 , where X 1 、X 2 and X 3 At least one of them is N.

[0045] In another preferred embodiment, R 15 Each occurrence is independently H, CN, halogen, OH, C 1-9 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl.

[0046] In another preferred embodiment, X 1 、X 2 and X 3 There is only one N or X 1 、X 2 and X 3 There are two N.

[0047] In another preferred embodiment, X 1 、X 2 and X 3 There is only X 3 is N.

[0048] In another preferred embodiment, m is 0.

[0049] In another preferred embodiment, wherein R 15 Both are H.

[0050] In another preferred embodiment, the compound has a structure shown in Formula III-1, III-2 or III-3:

[0051] Among them, each R 1 、R 3 、R 4、R 5 and R 6 Independently as defined herein.

[0052] In another preferred embodiment, the compound has a structure shown in Formula III-1a, III-2a or III-3a:

[0053] Among them, each R 1 、R 3 、R 4 、R 5 and R 6 Independently as defined herein.

[0054] In another preferred embodiment, R 5 Selected from hydrogen, halogen, -CN, -OR 7 、-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2. -C(O)R 7 、-C(O)N(R 7 )2、C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -OR 12 、C 1-9 Alkyl and aryl groups.

[0055] In another preferred embodiment, R 5 Selected from F, Cl, Br, CN,

[0056] In another preferred embodiment, R 6 is selected from hydrogen, methyl, ethyl or cyclopropyl.

[0057] In another preferred embodiment, R 6 For hydrogen.

[0058] In another preferred embodiment, R 3 is ethynyl or heteroaryl, wherein each ethynyl or heteroaryl optionally has 1 to 4 Z 3 .

[0059] In another preferred embodiment, the compound has a structure shown in Formula IV-1, IV-2 or IV-3:

[0060] Among them, each Z 3 、R 1 、R 4 、R 5 and R 6 Independently as defined herein.

[0061] In another preferred embodiment, the compound has a structure shown in Formula IV-1a, IV-2a or IV-3a:

[0062] Among them, each Z 3 、R 1 、R 4 、R 5 and R 6 Independently as defined herein.

[0063] In another preferred embodiment, Z 3 C 1-9 Alkyl, C 3-15 Cycloalkyl and heterocyclic groups; any C 1-9 Alkyl, C 3-15 Cycloalkyl and heterocyclyl are optionally selected from hydrogen, oxo, halogen, thio, -NO2, -CN, -N3, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 1-9 Alkoxy, amino, C 1-9 Alkylamino, (C 1-9 Alkyl)2amino, C 1-9 Halogenated alkyl, C 1-9 Alkylcarbonyl, C 1-9 The alkylsulfonyl group is substituted by 1 to 4 substituents selected from the group consisting of alkylsulfonyl, aryl, heteroaryl, and heterocyclic groups.

[0064] In another preferred embodiment, Z 3 Selected from

[0065] In another preferred embodiment, Z 3 Selected from

[0066] In another preferred embodiment, R 3 Selected from

[0067] In another preferred embodiment, R 4is a heterocyclic or heteroaryl group, and the heterocyclic or heteroaryl group is optionally substituted with 1 to 3 substituents independently selected from the following: -CN, halogen, -OR 12 、-C(O)-R 12 、C 1-9 Alkyl, C 1-9 Haloalkyl and heterocyclic groups.

[0068] In another preferred embodiment, R 4 Selected from

[0069] Furthermore, R 4 Selected from

[0070] In another preferred embodiment, X 1 and X 2 CH, X 3 is N, and R 5 For CN.

[0071] In another preferred embodiment, each X 1 、X 2 、X 3 、R 1 -R 6 、R 15 and m are independently the corresponding groups in the compounds described in the following table.

[0072] In another preferred embodiment, the compound is selected from:

[0073] In another preferred embodiment, the isotope substitute is deuterated.

[0074] In a second aspect, the present invention provides a pharmaceutical composition comprising the compound as described in the first aspect of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitution thereof, and a pharmaceutically acceptable carrier.

[0075] In another preferred embodiment, the pharmaceutical composition further comprises another therapeutic agent, such as an anti-inflammatory agent or an anti-cancer agent.

[0076] In a third aspect, the present invention provides the use of the compound described in the first aspect of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitution thereof, or the pharmaceutical composition described in the second aspect of the present invention in the preparation of a medicament for preventing or treating diseases or conditions mediated by Osaka thyroid carcinoma (Cot) kinase.

[0077] In another preferred embodiment, the disease or condition is selected from the following group: cancer, diabetes, and inflammatory diseases.

[0078] In another preferred embodiment, the disease or condition is selected from the group consisting of type 1 and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, dysregulated TNF expression and transplant rejection; acute gout and ankylosing spondylitis, allergic diseases, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis and multiple sclerosis, atherosclerosis, bacterial infection, bone cancer pain and endometriosis. Pain; BRAF-resistant melanoma, colon cancer, brainstem glioma or pituitary adenoma, burns, bursitis, cancer of the anal area, endocrine system cancer, kidney or ureter cancer (e.g., renal cell carcinoma, renal pelvis cancer), penile cancer, small intestine cancer, non-small cell lung cancer, thyroid cancer, urethral cancer, blood cancers such as acute myeloid leukemia, tongue cancer, cervical cancer, endometrial cancer, fallopian tube cancer, renal pelvis cancer, vaginal cancer, or vulvar cancer, chronic myeloid leukemia, chronic or acute leukemia, chronic pain, classic Bartter syndrome syndrome), common cold, conjunctivitis, coronary heart disease, skin or intraocular melanoma, dermatitis, dysmenorrhea, eczema, endometriosis, familial adenomatous polyposis, fibromyalgia, fungal infection, gout, gynecological cancer, uterine sarcoma, fallopian tube cancer, headache, hemophilic arthropathy, Parkinson's disease, AIDS, herpes zoster, Hodgkin's disease, Huntington's disease, hyperprostaglandin E syndrome, influenza, iritis, juvenile arthritis, juvenile-onset rheumatoid arthritis, juvenile rheumatoid arthritis, low back and neck pain, lymphocytic lymphoma, myofascial disorders, Myositis, neuralgia, neurodegenerative disorders such as Alzheimer's disease, neuroinflammatory disorders, neuropathic pain, vulvar cancer, Parkinson's disease, pediatric malignancies, pulmonary fibrosis, rectal cancer, rhinitis, sarcoidosis, soft tissue sarcoma, scleritis, skin cancer, solid tumors in children, spinal cord tumors, sprains and strains, gastric cancer, stroke, subacute and chronic musculoskeletal pain syndromes such as bursitis, surgical or dental procedures, symptoms associated with influenza or other viral infections, synovitis, toothache, ulcers, uterine cancer, uterine sarcoma, uveitis, vasculitis, viral infections, viral infections (e.g., influenza), and wound healing.

[0079] In a fourth aspect, the present invention provides use of the compound according to the first aspect of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope thereof in the preparation of an Osaka thyroid carcinoma (Cot) kinase inhibitor.

[0080] In a fifth aspect, the present invention provides an intermediate compound represented by formula M1:

[0081] Among them, R 16 is Cl, Br, I or OTf;

[0082] And X 1 、X 2 、X 3 、R 1 、R 2 、R 5 and R 15 As defined in the first aspect of the present invention.

[0083] In another preferred embodiment, the intermediate compound has a structure shown in formula M1a:

[0084] Among them, R 16 is Cl, Br, I or OTf;

[0085] And X 1 、X 2 、X 3 、R 1 、R 2 、R 5 and R 15 As defined in the first aspect of the present invention.

[0086] In the sixth aspect of the present invention, a method for inhibiting Cot activity is provided, which comprises contacting a cell with at least one compound according to the first aspect of the present invention or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitute thereof or the pharmaceutical composition, wherein the contact is in vitro, ex vivo or in vivo.

[0087] In the seventh aspect of the present invention, a method for treating a disease or condition mediated by Osaka thyroid carcinoma (Cot) kinase in a human patient in need thereof is provided, comprising the steps of administering to the patient a compound as described in the first aspect of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers or isotope thereof, or a composition as described in the second aspect of the present invention.

[0088] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION

[0089] After extensive and in-depth research, numerous screenings and tests, the present inventors have provided a class of novel structurally and highly effective Osaka thyroid carcinoma (Cot) kinase inhibitor compounds, on the basis of which the present invention was completed.

[0090] the term

[0091] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0092] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."

[0093] The prefix "C u-v " indicates that the following group has from u to v carbon atoms. For example, "C 1-9 "Alkyl" means an alkyl group having 1 to 9 carbon atoms. u-v "Includes all positive integers of C atoms between u and v, such as 1, 2, 3, 4, 5, 6, 7, 8, and 9 carbon atoms.

[0094] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, an alkyl group or a portion thereof having 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 9 carbon atoms (i.e., C 1-9 alkyl), 1 to 6 carbon atoms (i.e., C 1-6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 Alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbon atoms is named by chemical name or determined by molecular formula, all isomers having that number of carbon atoms are included; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3); and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0095] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (ie, C 2-4 Examples of the alkenyl group include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0096] "Alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20 Alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl), or 2 to 4 carbon atoms (i.e., C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0097] "Alkoxy" refers to the group "alkyl-O-," where alkyl is as defined above. Examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0098] "Haloalkoxy" refers to an alkoxy group as defined above wherein one or more hydrogen atoms are replaced by a halogen.

[0099] "Alkylthio" refers to the group "alkyl-S-."

[0100] "Acyl" refers to the group -C(O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0101] "Acylamino" refers to a "C-acylamino" group (which refers to the group -C(O)NR y R z ) and "N-amido" groups (which refer to the group -NR y C(O)R z ), where R y and R z are independently selected from hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.

[0102] "Amino" refers to the group -NR y Rz , where R y and R z are independently selected from hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.

[0103] "Amidino" refers to -C(NH)(NH2).

[0104] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) (including fused systems). As used herein, an aryl group has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 12 carbon ring atoms (i.e., C 6-12 aryl), or 6 to 10 carbon ring atoms (i.e., C 6-10 Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthracenyl. However, aryl groups do not include or overlap in any way with heteroaryl groups as defined below. If one or more aryl groups are fused to a heteroaryl group, the resulting ring system is a heteroaryl group. If one or more aryl groups are fused to a heterocyclyl group, the resulting ring system is a heterocyclyl group.

[0105] "Azide" refers to -N3.

[0106] "Carbamoyl" refers to an "O-carbamoyl" group (which refers to the group -OC(O)NR y R z ) and "N-carbamoyl" groups (which refer to the group -NR y C(O)OR z ), where R y and R z are independently selected from hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.

[0107] "Carboxyl" refers to -C(O)OH.

[0108] "Carboxyl ester" refers to -OC(O)R and -C(O)OR, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.

[0109] "Cyano" or "nitrile" refers to the group -CN.

[0110] "Cycloalkyl" refers to a saturated or partially unsaturated cyclic alkyl group having a single or multiple rings (including fused, bridged, and spirocyclic ring systems). The term "cycloalkyl" includes cycloalkenyl groups (i.e., the cyclic group has at least one double bond). Cycloalkyl groups, as used herein, have from 3 to 20 ring carbon atoms (i.e., C 3-20cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 Examples of the cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0111] "Guanidino" refers to -NHC(NH)(NH2).

[0112] "Hydrazino" refers to -NHNH2.

[0113] "Imino" refers to the group -C(NR)R, where each R is alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.

[0114] "Halogen" or "halogenated" includes fluorine, chlorine, bromine, and iodine.

[0115] "Haloalkyl" refers to an unbranched or branched alkyl group as defined above in which one or more hydrogen atoms are replaced by a halogen. For example, when a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl groups substituted with two ("di") or three ("tri") halogen groups, which may be, but need not be, the same halogen. Examples of haloalkyl groups include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0116] "Heteroalkyl" refers to an alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are each independently replaced by the same or different heteroatom groups. The term "heteroalkyl" includes unbranched or branched saturated chains having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced by the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, -S(O)2-, etc., where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclic radical, each of which may be optionally substituted. Examples of heteroalkyl groups include -OCH3, -CHOCH3, -SCH3, -CH2SCH3, -NRCH3 and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl or heteroaryl, each of which may be optionally substituted. As used herein, a heteroalkyl group contains 1-10 carbon atoms, 1-8 carbon atoms, or 1-4 carbon atoms; and 1-3 heteroatoms, 1-2 heteroatoms, or 1 heteroatom.

[0117] "Heteroaryl" refers to an aromatic group having a monocyclic, multiple, or multiple fused rings, wherein one or more ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As described herein, heteroaryl includes 5 to 20 ring atoms (i.e., 5-20 membered heteroaryl), 5 to 12 ring atoms (i.e., 5-12 membered heteroaryl), or 6 to 10 ring atoms (i.e., 6-10 heteroaryl); wherein, 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, wherein the ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl include pyrimidinyl, purinyl, pyridinyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolyl, isoquinolyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, wherein the heteroaryl group may be attached through any ring of the fused system. Any aromatic ring with single or multiple fused rings containing at least one heteroatom is considered a heteroaryl group, regardless of attachment to the rest of the molecule (i.e., through any of the fused rings). Heteroaryl groups do not include or overlap with aryl groups as defined above.

[0118] "Heterocyclic radical" refers to a saturated or unsaturated cycloalkyl radical having one or more ring heteroatoms independently selected from nitrogen, oxygen and sulphur. The term "heterocyclic radical" includes heterocyclenyl (i.e., a heterocyclic radical having at least one double bond), bridged heterocyclic radical, fused heterocyclic radical and spiral-heterocyclic radical. A heterocyclic radical can be a monocyclic or polycyclic ring, wherein the polycyclic ring can be fused, bridged or spirocyclic. Any non-aromatic ring containing at least one heteroatom is considered to be a heterocyclic radical, regardless of connection (i.e., it can be combined by carbon atoms or heteroatoms). In addition, the term heterocyclic radical is intended to include any non-aromatic ring containing at least one heteroatom, which ring can be fused to an aryl or heteroaryl ring, regardless of connection to the rest of the molecule. As used herein, the heterocyclic group has 3 to 20 ring atoms (i.e., 3-20 membered heterocyclic groups), 4 to 12 ring atoms (i.e., 4-12 membered heterocyclic groups), 5 to 10 ring atoms (i.e., 5-10 membered heterocyclic groups), 6 to 7 ring atoms (i.e., 6-8 membered heterocyclic groups), or 3 to 6 ring atoms (i.e., 3-6 membered heterocyclic groups); wherein, there may be 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, the ring heteroatoms being independently selected from nitrogen, sulfur or oxygen. The heterocyclic group may include one or more oxo and / or thio groups. Examples of heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolane, azetidinyl, and morpholinyl. As used herein, the term "bridged-heterocyclic radical" refers to a 4 to 10 ring moiety that is connected to a 4 to 10 ring moiety having at least one heteroatom at two non-adjacent atoms of a heterocyclic radical with one or more (e.g., 1 or 2), wherein each heteroatom is independently selected from nitrogen, oxygen, and sulphur."bridged-heterocyclic radical" as used herein includes bicyclic and tricyclic ring systems. In addition, as used herein, the term "spiro-heterocyclic radical" refers to a ring system in which a 3- to 10-membered heterocyclic radical has one or more other rings, wherein the one or more other rings are 3- to 10-membered cycloalkyl or 3- to 10-membered heterocyclic radicals, wherein the single atom of the one or more other rings is also an atom of the 3- to 10-membered heterocyclic radical. Examples of spiro-heterocyclyl rings include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.4]octyl, and 6-oxa-1-azaspiro[3.3]heptyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 1-oxo-1,2,3,4-tetrahydroisoquinolinyl, 1-oxo-1,2-dihydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, wherein the heterocyclyl group may be attached through any ring of the fused system.

[0119] "Hydroxy" or "hydroxyl" refers to the group -OH. "Hydroxyalkyl" refers to an unbranched or branched alkyl group as defined above in which one or more hydrogen atoms are replaced by a hydroxy group.

[0120] "Oxo" refers to the group (=O) or (O).

[0121] "Nitro" refers to the radical -NO2.

[0122] "Sulfonyl" refers to the group -S(O)2R, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl. "Alkylsulfonyl" refers to the group -S(O)2R, where R is alkyl.

[0123] "Alkylsulfinyl" refers to the group -S(O)R, where R is alkyl.

[0124] "Thiocyanate" refers to -SCN.

[0125] "Mercapto" refers to the group -SR, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl.

[0126] "Thio" or "thioketo" refers to the group (=S) or (S).

[0127] Some commonly used alternative chemical names may be used. For example, divalent groups such as divalent "alkyl" and divalent "aryl" may also be referred to as "alkylene" or "alkylenyl" or "arylene" or "arylenyl," respectively. In addition, unless otherwise defined, when a combination of groups is referred to herein as a moiety (e.g., arylalkyl), the last mentioned group contains the atom that connects the moiety to the rest of the molecule.

[0128] The term "1 to n" may refer to any positive integer from 1 to n, such as 1, 2, 3, 4, ..., n.

[0129] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where said event or circumstance does not occur. Additionally, the term "optionally substituted" means that any one or more hydrogen atoms on a designated atom or group may or may not be replaced with a moiety other than hydrogen.

[0130] The term "substituted" means that any one or more hydrogen atoms on a designated atom or group are replaced by a moiety other than hydrogen, provided that the normal valence of the designated atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amide, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halogen, haloalkyl, haloalkoxy, heteroalkyl, heteroaryl, heterocyclyl, hydroxyl, hydrazine, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, sulfhydryl, thioketone, or a combination thereof. It is contemplated that polymers or similar indefinite structures obtained by further defining substituents with additional substituents are not included herein (e.g., substituted aryl with substituted alkyl, the substituted alkyl itself substituted with substituted aryl, the substituted aryl further substituted with substituted heteroalkyl, etc.). Unless otherwise stated, the maximum number of consecutive substitutions in the compounds described herein is 3. For example, the continuous substitution of a substituted aryl by two other substituted aryls is limited to an aryl substituted by a substituted aryl (substituted aryl). Similarly, the above definition is intended to exclude unallowed substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl with two adjacent oxygen ring atoms). These unallowed substitution patterns are well known to those skilled in the art. When used to modify a chemical group, the term "substituted" may describe other chemical groups defined herein. Unless otherwise stated, when a group is described as optionally substituted, any substituent of the group is itself unsubstituted. For example, in some embodiments, the term "substituted alkyl" refers to an alkyl group with one or more substituents, including hydroxyl, halogen, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl. In other embodiments, the one or more substituents may be further substituted by halogen, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, and each of the above groups is substituted. In other embodiments, the substituents may be further substituted with halogen, alkyl, haloalkyl, alkoxy, hydroxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.

[0131] Active ingredient

[0132] The present invention provides a compound of formula I:

[0133] where X 1 、X 2 、X 3 、R 1 -R 6 、R 15 and m as described herein.

[0134] Also provided are pharmaceutically acceptable salts, tautomers, stereoisomers, mixtures of stereoisomers, or isotopic substitutes thereof of the compounds described herein.

[0135] In many cases, the compounds of the present invention are capable of forming acid and / or base salts due to the presence of amino and / or carboxyl groups or similar groups. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts formed with inorganic acids or with organic acids. In addition, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt, specifically a pharmaceutically acceptable addition salt, can be produced according to conventional procedures for preparing acid addition salts from base compounds by dissolving the free base in a suitable organic solvent and treating the solution with an acid. Those skilled in the art will be aware of various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Inorganic acids from which salts can be derived include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. By way of example only, salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkylamines (i.e., NH2(alkyl)), dialkylamines (i.e., HN(alkyl)2), trialkylamines (i.e., N(alkyl)3), substituted alkylamines (i.e., NH2(substituted alkyl)), di(substituted alkyl)amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl)amines (i.e., N(substituted alkyl)3), alkenylamines (i.e., NH2(alkenyl)), dienylamines (i.e., HN(alkenyl)2), trialnylamines (i.e., N(alkenyl)3), substituted alkenylamines (i.e., NH2(substituted alkenyl)), di(substituted

[0014] The present invention also provides a substituted alkenyl)amine (i.e., HN(substituted alkenyl)2), a tri(substituted alkenyl)amine (i.e., N(substituted alkenyl)3), a mono-, di- or tri-cycloalkylamine (i.e., NH2(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), a mono-, di- or tri-arylamine (i.e., NH2(aryl), HN(aryl)2, N(aryl)3), or a mixed amine, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0136] Some compounds exist in tautomer forms. Tautomers are in equilibrium with each other. For example, compounds containing amides can exist in equilibrium with imidic acid tautomers. No matter which tautomer is shown, and no matter how the nature of the equilibrium between the tautomers is, those of ordinary skill in the art will understand that the compound comprises amides and imidic acid tautomers. Therefore, compounds containing amides are understood to include their imidic acid tautomers. Similarly, compounds containing imidic acid are understood to include their amide tautomers.

[0137] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, geometric isomers, regioisomers, and individual isomers (e.g., isolated enantiomers) are intended to be encompassed within the scope of the present invention. When compounds provided herein have defined stereochemistry (denoted as R or S, or indicated by dashed or wedge-shaped bonds), those skilled in the art will understand that those compounds are substantially free of other isomers (e.g., at least 80%, 90%, 95%, 98%, 99%, and up to 100% free of other isomers).

[0138] Any formula or structure given in this application is also intended to represent unlabeled forms of the compound as well as isotopically labeled forms. An isotopically labeled compound has a structure described by the formula given in this application except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I. The present invention includes various isotopically labeled compounds of the present invention, for example, those labeled with radioactive isotopes such as 3 H. 13 C and 14 Such isotopically labeled compounds are useful in metabolism studies, reaction kinetic studies, detection or imaging techniques, such as nuclear magnetic resonance imaging (NMR), positron emission tomography (PET), or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution assays, or in radiotherapy of patients.

[0139] The present disclosure also includes "deuterated analogs" of compounds of Formula I in which 1 to n (where n is the number of hydrogens in the molecule) hydrogens attached to carbon atoms are replaced by deuterium. Such compounds exhibit enhanced resistance to metabolism and are therefore useful for increasing the half-life of any compound of Formula I when administered to a mammal, particularly a human. Such compounds are synthesized by methods known in the art, for example, by using starting materials in which one or more hydrogen atoms have been replaced by deuterium.

[0140] Deuterium-labeled or substituted therapeutic compounds of the present invention can have improved DMPK (drug metabolism and pharmacokinetics) properties, which relate to distribution, metabolism and excretion (ADME). Using heavier isotope (e.g., deuterium) substitution can provide some therapeutic advantages based on larger metabolic stability, such as increased half-life in vivo, reduced dosage requirements and / or improved therapeutic index. 18 F-labeled compounds can be used for PET or SPECT studies. Isotopically labeled compounds of the present invention and their prodrugs are generally prepared by utilizing the synthetic routes described below or the steps described in the examples and preparations, wherein non-isotopically labeled reagents are replaced with readily available isotopically labeled reagents. It is understood that deuterium in this application can be considered a substituent of a compound of Formula I.

[0141] The concentration of such heavier isotopes (specifically deuterium) can be defined by an isotopic enrichment factor. In the compounds of the present invention, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen," it is understood that the position is a hydrogen with its natural abundance isotopic composition. Thus, in the compounds of the present invention, any atom specifically designated as deuterium (D) is meant to represent deuterium.

[0142] The present invention also provides the compound or its pharmaceutically acceptable hydrates, solvates, polymorphs, active metabolites and prodrugs.

[0143] A "solvate" is formed by the interaction of a solvent and a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.

[0144] In certain embodiments, prodrugs of the compounds described herein are provided. "Prodrug" refers to any compound that, when administered to a biological system, produces a drug substance or active ingredient due to a spontaneous chemical reaction, an enzyme-catalyzed chemical reaction, photolysis, and / or metabolic chemical reaction. A prodrug is thus a covalently modified analog or latent form of a therapeutically active compound. Non-limiting examples of prodrugs include ester moieties, quaternary ammonium moieties, ethylene glycol moieties, and the like.

[0145] Also provided herein are in vivo metabolic products of the compounds described herein. Such products may result, for example, from oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound, primarily due to enzymatic processes.

[0146] use

[0147] Experiments have shown that the compounds of the present invention can specifically inhibit Osaka thyroid carcinoma (Cot) kinase, and thus can be used to prevent or treat diseases or symptoms mediated by Osaka thyroid carcinoma (Cot) kinase.

[0148] As used herein, "treat" refers to an agent used to obtain a beneficial or desired result (including a clinical result). Beneficial or desired clinical results may include one or more of the following: a) inhibiting a disease or condition (e.g., reducing one or more symptoms caused by the disease or condition and / or alleviating the severity of the disease or condition); b) slowing or preventing the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread of the disease or condition (e.g., metastasis)); and / or c) alleviating the disease, i.e., causing regression of clinical symptoms (e.g., improving the disease state, providing partial or complete relief of the disease or condition, enhancing the effects of other drug therapies, delaying disease progression, improving quality of life, and / or prolonging survival).

[0149] "Prevention" or "prevention" refers to any treatment of a disease or condition so that clinical symptoms of the disease or condition do not appear. In some embodiments, the compound can be administered to a subject (including a human) at risk for a disease or condition or with a family history of the disease or condition.

[0150] The term "therapeutically effective amount" or "effective amount" of a compound described herein, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, refers to an amount sufficient to achieve treatment when administered to a subject, to provide a therapeutic benefit, such as improving symptoms or slowing disease progression. For example, a therapeutically effective amount may be an amount sufficient to reduce the symptoms of a disease or condition responsive to inhibition of Cot activity. The therapeutically effective amount may vary depending on the subject and the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, and the mode of administration, which can be readily determined by one of ordinary skill in the art.

[0151] The term "inhibit" indicates a decrease in the baseline activity of a biological activity or process. "Inhibition of the activity of COT" or variations thereof refers to a decrease in the activity of COT in the presence of a compound of the invention, directly or indirectly, relative to the activity of COT in the absence of a compound of the invention. "Inhibition of COT" refers to a decrease in the activity of COT in the presence of a compound described herein, directly or indirectly, relative to the activity of COT in the absence of a compound described herein. In some embodiments, inhibition of COT activity can be compared to the same subject before treatment, or compared to other subjects not receiving the treatment.

[0152] The methods described herein can be applied to in vivo or ex vivo cell colonies. "In vivo" means within a living individual, such as an animal or human body. In this case, the methods described herein can be used therapeutically in an individual. "Ex vivo" means outside a living individual. Examples of ex vivo cell colonies include in vitro cell cultures and biological samples, including fluid or tissue samples obtained from an individual. Such samples can be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the compounds and compositions described herein can be used for various purposes, including therapeutic and experimental purposes. For example, the compounds and compositions described herein can be used ex vivo to determine the optimal dosing schedule and / or dosage of Cot selective inhibitors for specified indications, cell types, individuals, and other parameters. The information collected from such uses can be used for experimental purposes or in the clinic to set an in vivo treatment regimen. Other ex vivo uses to which the compounds and compositions described herein may be suitable are described below or should be clear to those skilled in the art. The selected compounds can be further characterized to check safety or tolerable doses in humans or non-human subjects. Such properties can be examined using methods generally known to those skilled in the art.

[0153] The compounds disclosed herein can be used to prepare a medicament for preventing or treating a disease or condition mediated by Cot kinase, or for a method of treating a disease or condition mediated by Cot. Non-limiting examples of diseases or conditions mediated by Cot include, but are not limited to, cancer, diabetes, and inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, dysregulated TNF expression, and transplant rejection.

[0154] In some embodiments, the disease or condition mediated by Cot is a solid tumor. In a specific embodiment, the solid tumor is selected from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, kidney cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, cervical cancer, stomach cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumor (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma. In some embodiments, the solid tumor is selected from non-small cell lung cancer, small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, kidney cancer, prostate cancer, or breast cancer.

[0155] In some embodiments, the disease or condition mediated by Cot is diabetes, which includes any metabolic disorder characterized by impaired insulin production and glucose tolerance. In some embodiments, diabetes includes type 1 and type 2 diabetes, gestational diabetes, prediabetes, insulin resistance, metabolic syndrome, impaired fasting glucose, and glucose intolerance. Type 1 diabetes is also known as insulin-dependent diabetes mellitus (IDDM). Type 2 diabetes is also known as non-insulin-dependent diabetes mellitus (NIDDM).

[0156] In some embodiments, the disease or illness mediated by Cot is an inflammatory disease or LPS-induced endotoxic shock. In some embodiments, the disease is an autoimmune disease. In a specific embodiment, the autoimmune disease is systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, Sjögren's syndrome, autoimmune hemolytic anemia, asthma or chronic obstructive pulmonary disease (COPD), ankylosing spondylitis, acute gout and ankylosing spondylitis, reactive arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, juvenile arthritis, juvenile onset rheumatoid arthritis, juvenile rheumatoid arthritis or psoriatic arthritis. In other embodiments, the disease is inflammation. In other embodiments, the disease is an excessive or destructive immune response, such as asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.

[0157] In some embodiments, the disease or condition mediated by Cot is inflammatory bowel disease (IBD).As used herein, the term "inflammatory bowel disease" or "IBD" is a general term describing inflammatory conditions of the gastrointestinal tract, the most common forms of which are ulcerative colitis and Crohn's disease. Other forms of IBD that can be treated with the compounds, compositions, and methods disclosed herein include diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis (autistic enterocolitis), indeterminate colitis, Behçet's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation-induced enteritis, short bowel syndrome, celiac disease, gastric ulcer, diverticulitis, pouchitis, proctitis, and chronic diarrhea.

[0158] Treatment or prevention of IBD also includes improving or alleviating one or more symptoms of IBD. As used herein, the term "symptoms of IBD" refers to detected symptoms, such as abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite and other more serious complications, such as dehydration, anemia and malnutrition. A variety of these symptoms are subjected to quantitative analysis (e.g., weight loss, fever, anemia, etc.). Some symptoms are easily determined based on blood tests (e.g., anemia) or tests that detect the presence of blood (e.g., rectal bleeding). The term "wherein alleviating these symptoms" refers to a qualitative or quantitative alleviation of detectable symptoms, including, but not limited to, a detectable effect on the rate of recovery from the disease (e.g., rate of weight gain). Diagnosis is typically determined by endoscopic observation of the mucosa and pathological examination of endoscopic biopsy samples.

[0159] The course of IBD varies and is generally associated with intermittent periods of remission and exacerbation. Various methods have been described to characterize the disease activity and severity of IBD and the response to treatment of subjects with IBD. Treatment according to the methods of the present invention is generally applicable to subjects with IBD at any level or degree of disease activity.

[0160] In some embodiments, the diseases or conditions treated by administering a compound of the compositions described herein include acute gout and ankylosing spondylitis, allergic diseases, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis and multiple sclerosis, atherosclerosis, bacterial infections, bone cancer pain and pain caused by endometriosis, BRAF-resistant melanoma, brain stem glioma or pituitary adenoma, burns, bursitis, cancer of the anal region, cancer of the endocrine system, cancer of the kidney or ureter (e.g., renal cell carcinoma, renal pelvis cancer), cancer of the penis, cancer of the small intestine, cancer of the thyroid gland, cancer of the urethra, blood cancers such as acute myeloid leukemia, cancer of the tongue, cancer of the cervix, cancer of the endometrium, cancer of the fallopian tube, cancer of the renal pelvis, cancer of the vagina or vulva, chronic myeloid leukemia, chronic or acute leukemia, chronic pain, classic Bartter syndrome (e.g., Bartter syndrome), syndrome), common cold, conjunctivitis, coronary heart disease, skin or intraocular melanoma, dermatitis, dysmenorrhea, eczema, endometriosis, familial adenomatous polyposis, fibromyalgia, fungal infection, gout, gynecological cancer, uterine sarcoma, fallopian tube cancer, headache, hemophilic arthropathy, Parkinson's disease, AIDS, herpes zoster, Hodgkin's disease, Huntington's disease, hyperprostaglandin E syndrome, influenza, iritis, juvenile arthritis, juvenile-onset rheumatoid arthritis, juvenile rheumatoid arthritis, low back and neck pain, lymphocytic lymphoma, myofascial disorders, Myositis, neuralgia, neurodegenerative disorders such as Alzheimer's disease, neuroinflammatory disorders, neuropathic pain, vulvar cancer, Parkinson's disease, pediatric malignancies, pulmonary fibrosis, rectal cancer, rhinitis, sarcoidosis, soft tissue sarcoma, scleritis, skin cancer, solid tumors in children, spinal cord tumors, sprains and strains, gastric cancer, stroke, subacute and chronic musculoskeletal pain syndromes such as bursitis, surgical or dental procedures, symptoms associated with influenza or other viral infections, synovitis, toothache, ulcers, uterine cancer, uterine sarcoma, uveitis, vasculitis, viral infections, viral infections (e.g., influenza), and wound healing.

[0161] In some embodiments, the Cot-mediated disease or condition is alcoholic hepatitis. Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver failure in subjects with chronic and active alcohol abuse (see Akriviadis E. et al., Ann Gastroenterol. 2016 Apr-Jun; 29(2): 236-237). Alcoholic hepatitis can cause cirrhosis and hepatocellular fibrosis. Glucocorticoids (e.g., prednisolone) and phosphodiesterase inhibitors (e.g., pentoxifylline) can be used to treat alcoholic hepatitis. The compounds herein can be used as a single treatment or in combination with current alcoholic hepatitis treatments.

[0162] In some embodiments, the Cot-mediated disease or condition is systemic lupus erythematosus (SLE), lupus nephritis, lupus-related or other autoimmune diseases or SLE symptoms. Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, mouth ulcers, swollen lymph nodes, sensitivity to sunlight, rash, headache, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythm, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon.

[0163] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation, or experiment. The methods described herein can be used for human therapy and veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

[0164] Combination therapy

[0165] In one embodiment, the compounds disclosed herein can be used in combination with one or more other therapeutic agents being used and / or developed to treat inflammatory disorders (e.g., IBD). The one or more additional therapeutic agents can be an α4β7 inhibitor, a steroid, an MMP-9 antibody, an S1P1 agonist, a TNF biologic, or any combination thereof.

[0166] In some embodiments, the one or more other therapeutic agents may be an α4β7 integrin inhibitor, or an agent that inhibits the expression and / or activity of the α4β7 integrin. The inhibitor may be a small molecule or a biologic. For example, the α4β7 integrin inhibitor may be natalizumab or vedolizumab.

[0167] In some embodiments, the one or more additional therapeutic agents may be steroids, including but not limited to corticosteroids. Corticosteroids can be administered by a variety of routes, including intravenous (i.e., methylprednisolone, hydrocortisone), oral (i.e., prednisone, prednisolone, budesonide, dexamethasone), or topical (i.e., enema, suppository, or foam formulation).

[0168] In some embodiments, the one or more other therapeutic agents may be a TNF inhibitor, or an agent that inhibits the expression and / or activity of TNF. The inhibitor may be a small molecule or a biologic. For example, the TNF inhibitor may be golimumab.

[0169] In some embodiments, the one or more additional therapeutic agents are being used and / or developed to treat ulcerative colitis (UC) and / or Crohn's disease (CD).

[0170] In some embodiments, the one or more additional therapeutic agents may be a JAK inhibitor, particularly a JAK-1 selective inhibitor. The inhibitor may be a small molecule or a biologic. For example, the JAK inhibitor may be filgotinib or GLPG0634 (a JAK modulator from Galápagos).

[0171] Pharmaceutical composition and administration method

[0172] The compound provided herein is usually administered in the form of a pharmaceutical composition. Therefore, a pharmaceutical composition is also provided herein, which comprises one or more compounds described herein or their pharmaceutically acceptable salts, tautomers, stereoisomers, stereoisomer mixtures, prodrugs or their isotope substitutes, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable carriers may include, for example, inert solid diluents and fillers, diluents (including sterile aqueous solutions and various organic solvents), penetration enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner known to the pharmaceutical field.

[0173] "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials that are suitable for use in preparing pharmaceutical compositions for veterinary or human medical use.

[0174] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings / coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Such media and agents for pharmaceutically active substances are well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, their use in therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the compositions.

[0175] The pharmaceutical composition can be administered in a single dose or multiple doses. The pharmaceutical composition can be administered by various methods, including, for example, rectal, buccal, intranasal, and transdermal routes. In certain embodiments, the pharmaceutical composition can be administered by intraarterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or inhaled form.

[0176] One mode of administration is parenteral, for example, by injection. Forms that can be incorporated into the pharmaceutical compositions described herein for administration by injection include, for example, aqueous or oily suspensions or emulsions containing sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or sterile aqueous solutions and similar pharmaceutical vehicles.

[0177] Oral administration can be another route for administering the compounds described herein. For example, administration can be via capsules or enteric-coated tablets. In the preparation of pharmaceutical compositions comprising at least one compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, the active ingredient is typically diluted with an excipient and / or encapsulated in a carrier that can be in the form of a capsule, pouch, paper, or other container. When an excipient is used as a diluent, it can be in the form of a solid, semisolid, or liquid material (as described above) that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, pouches, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid form or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

[0178] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, sterile water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents.

[0179] The composition comprising at least one compound as described herein or its pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug or deuterated analogue can be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to the subject by adopting operations known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolution systems, which contain polymer-coated reservoirs or drug-polymer matrix formulations. Another formulation used in the method disclosed herein adopts a transdermal delivery device ("patch"). Such transdermal patches can be used to provide compounds as described herein for continuous or discontinuous infusion in controlled amounts.

[0180] For the preparation of solid compositions such as tablets, the principal active ingredient can be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug or deuterated analog thereof. When referring to these preformulation compositions as homogeneous compositions, the active ingredient is dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

[0181] The tablets or pills of the compounds described herein can be coated or otherwise mixed to provide a dosage form that has an advantage of prolonged action time or protection from the acidic conditions of the stomach. For example, a tablet or pill can include an inner dose and an outer dose component, the latter being an encapsulated form on the former. The two components can be separated by an enteric layer to resist disintegration in the stomach and to allow the inner component to enter the duodenum intact or to delay release. Many materials can be used as the enteric layer or coating, including many polymeric acids, and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0182] Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein. In some embodiments, the compositions are administered by oral or nasal respiratory routes for local or systemic effect. In other embodiments, the compositions in pharmaceutically acceptable solvents may be aerosolized using an inert gas. The aerosolized solution may be inhaled directly from the aerosolizing device or the aerosolizing device may be connected to a mask holder or an intermittent positive pressure breathing machine. The solution, suspension, or powder composition may preferably be administered orally or nasally from a device that delivers the formulation in an appropriate manner.

[0183] Drug administration

[0184] For any specific subject, the specific dosage level of the compound of the present application will depend on a variety of factors, including the activity of the specific compound used in the subject undergoing therapy, age, body weight, overall health, sex, diet, administration time, route of administration and excretion rate, drug combination and the severity of the specific disease. For example, the dosage can be expressed as milligrams of the compound described herein per kilogram of subject body weight (mg / kg). A dosage of about 0.1 to 150 mg / kg may be appropriate. In some embodiments, about 0.1 to 100 mg / kg may be appropriate. In other embodiments, a dosage of 0.5 to 60 mg / kg may be appropriate. When adjusting the dosage between subjects with widely different body sizes, for example, when using the drug in children and adults or when converting the effective dose in non-human subjects (e.g., dogs) to a dosage suitable for human subjects, standardization according to the subject's weight is particularly applicable.

[0185] The daily dose can also be described as the total amount of a compound described herein administered per dose or per day. The daily dose of a compound of Formula I can be about 1 mg to 4,000 mg, about 2,000 to 4,000 mg / day, about 1 to 2,000 mg / day, about 1 to 1,000 mg / day, about 10 to 500 mg / day, about 20 to 500 mg / day, about 50 to 300 mg / day, about 75 to 200 mg / day, or about 15 to 150 mg / day.

[0186] When administered orally, the total daily dose for a human subject can be 1 mg to 1,000 mg, about 1,000-2,000 mg / day, about 10-500 mg / day, about 50-300 mg / day, about 75-200 mg / day, or about 100-150 mg / day.

[0187] The compounds of the present application or compositions thereof can be administered once, twice, three times or four times daily using any suitable mode described above. In addition, the administration or treatment of the compound can be continuous for multiple days; for example, for a treatment cycle, the treatment will generally last for at least 7 days, 14 days or 28 days. Treatment cycles are well known in cancer chemotherapy and are often alternating with rest periods of about 1 to 28 days, typically about 7 days or about 14 days, between multiple cycles. In other embodiments, the treatment cycles can also be continuous.

[0188] In one embodiment, the method comprises administering to a subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose in increments until clinical efficacy is achieved. The dose may be increased in increments of about 5, 10, 25, 50, or 100 mg. The dose may be increased daily, every other day, twice a week, or once a week.

[0189] Preparation method, intermediates

[0190] The compounds of the present invention have no particular requirements for the preparation method and can be prepared according to their chemical structures by referring to commonly used organic synthesis methods in the art, or by referring to the methods described below in the present invention.

[0191] The present invention also provides a key intermediate that can be used to prepare the compound of the present invention:

[0192] Among them, R 16 is Cl, Br, I or OTf;

[0193] And X 1 、X 2 、X 3 、R 1 、R 2 、R 5 and R 15 As defined herein.

[0194] The main advantages of the present invention include:

[0195] 1. The present invention provides a novel class of Osaka thyroid carcinoma (Cot) kinase inhibitors.

[0196] 2. The compounds of the present invention have excellent Osaka thyroid carcinoma (Cot) kinase inhibitory activity and can specifically inhibit Osaka thyroid carcinoma (Cot) kinase, thereby preventing or / treating related diseases.

[0197] 3. The compounds of the present invention have good pharmacokinetic properties (such as longer half-life and higher bioavailability) and pharmacodynamic properties, as well as excellent drugability, and are very suitable for the preparation of drugs for preventing and / or treating diseases or conditions mediated by Osaka thyroid carcinoma (Cot) kinase.

[0198] The present invention will be further described below in conjunction with specific implementation. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0199] Synthesis process

[0200] Abbreviation Definition

[0201] Certain abbreviations are defined as follows: “°C” means degrees Celsius; “Ac” means acetyl; “ATP” means adenosine triphosphate; “Boc” means tert-butyloxycarbonyl; “br” means broad; “BSA” means bovine serum albumin; “Cbz” means carbonylbenzyl; “ChEF” means chelate-enhanced fluorescence; “COPD” means chronic obstructive pulmonary disease; “Cot” means Osaka thyroid carcinoma; “d” means doublet; “DCM” means dichloromethane; “dd” means doublet of doublet; “DIPEA” means N,N-diisopropylethylamine; “DMF” means N,N-dimethylformamide; “DMSO” means dimethyl sulfoxide; “dppf” means 1,1′-bis(diphenylphosphino)ferrocene; “dt” means doublet of triplet; “DTT” means dithiothreitol; “EA” means ethyl acetate; “EGF” means iodine. “R” refers to epidermal growth factor receptor; “EGTA” refers to ethylene glycol bis(2-aminoethyl ether) tetraacetic acid; “eq” refers to equivalents; “ES / MS” refers to electrospray ionization mass spectrometry; “Et” refers to ethyl; “FA” refers to formic acid; “g” refers to grams; “HATU” refers to 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; “HEPES” refers to 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; “HPLC” refers to high pressure liquid chromatography; “Hz” refers to hertz; “IBD” refers to inflammatory bowel disease; “i-Pr” refers to isopropyl; “J” refers to coupling constant (MHz); “LPS” refers to lipopolysaccharide; “LTBA” refers to lithium tri-tert-butyloxyaluminum hydride; “MS” refers to mass spectrometry; “M” refers to molarity; “m” refers to multiplet; “M+H” refers to chromatographic markers. + ” refers to proton peak + hydrogen; “Me” refers to methyl; “mg” refers to milligram; “MHz” refers to megahertz; “min” refers to minute; “mL” refers to milliliter; “mM” refers to millimolar; “mmol” refers to millimolar; “MS” refers to mass spectrometry; “Ms” refers to methanesulfonyl; “nBu / Bu” refers to butyl; “NBS” refers to N-bromosuccinimide; “nL” refers to nanoliter; “nm” refers to nanometer; “NMR” refers to nuclear magnetic resonance; “Pd / C” refers to palladium / carbon; “PE” refers to petroleum ether; “ "Ph" refers to phenyl; "PS" refers to polystyrene; "q" refers to quartet; "rt" refers to room temperature; "s" refers to singlet; "t" refers to triplet; "t-Bu" refers to tert-butyl; "Tf" refers to trifluoromethanesulfonyl; "TFA" refers to trifluoroacetic acid; "TFAA" refers to trifluoroacetic anhydride; "THF" refers to tetrahydrofuran; "Tpl2" refers to tumor progression locus 2; "TNF" refers to tumor necrosis factor; "δ" refers to chemical shift (ppm); "μL" refers to microliter; "μM" refers to micromolar;

[0202] Process 1

[0203] In Scheme 1, Step A describes the diazotization of compound 1 with a diazotizing agent (e.g., sodium nitrite, etc.) in a suitable solvent (e.g., concentrated hydrochloric acid, etc.), followed by reaction with compound 2 to produce hydrazone compound 3. Step B shows the conversion of compound 3 to compound 4 in a suitable solvent (e.g., chlorobenzene, etc.) in the presence of a catalyst (e.g., AlCl3, etc.) at an elevated temperature (e.g., about 110°C). Step C shows the hydrolysis of compound 4 with a suitable inorganic base (e.g., KOH, etc.) in a suitable solvent (e.g., DMSO, H2O, etc.) to produce compound 5. Step D describes the post-treatment of compound 5 with aqueous ammonia using a suitable chlorinating agent (e.g., SOCl2, POCl3, etc.) at an elevated temperature (e.g., about 110-120°C) in the presence of a catalyst (e.g., DMF, etc.) to produce compound 6. Step E shows the conversion of compound 6 to compound 7 with a suitable dehydrating agent (e.g., POCl3, etc.) at an elevated temperature (e.g., about 110°C). Step F describes the reaction of compound 7 with a suitable amine under standard nucleophilic aromatic substitution conditions in the presence of a base (eg, DIPEA, etc.) and at elevated temperature (eg, about 75° C.) to provide compound 8.

[0204] Process 2

[0205] In Scheme 2, Step A shows that compound 10 can be provided by reacting an appropriately substituted aldehyde 9 with an acetylene Grignard reagent, followed by acylation of the resulting alcohol with acetic anhydride.

[0206] Process 3

[0207] In Scheme 3, Step A describes the treatment of an appropriately substituted amine 11 with a diazo transfer reagent (e.g., imidazole-1-sulfonyl azide hydrochloride) to provide the corresponding compound 12. Step B shows that an appropriately substituted triazole 13 can be obtained by reacting compound 12 with methyl propiolate via standard 1,3-dipolar cycloaddition conditions. Step C describes the hydrolysis of compound 13 in a suitable inorganic base (e.g., NaOH, etc.) in a suitable solvent (e.g., THF, H2O, etc.) to provide compound 14. Step D describes the reaction of compound 14 with an inorganic base (e.g., sodium acetate, etc.) in a solvent (e.g., H2O, etc.) at an elevated temperature (e.g., about 75°C) in the presence of a brominating agent (e.g., NBS, etc.) to provide compound 15. Step E shows that compound 16 is prepared by the following method by reacting compound 15 with compound 9 in a solvent (e.g., THF, etc.) in the presence of an organometallic reagent (e.g., isopropylmagnesium chloride lithium chloride complex, etc.) to provide compound 16. Step F shows that compound 16 is treated with an oxidizing agent (e.g., Dess-Martin reagent, etc.) to obtain compound 17. Step G describes the reaction of compound 17 with tert-butylsulfenamide in the presence of a titanium- or zirconium-based reagent in a suitable solvent (e.g., toluene, etc.) at a suitable temperature (e.g., about 75° C.) to obtain compound 18. Step H describes the reaction of compound 18 with a reducing agent (e.g., LTBA, etc.) to obtain compound 19. Step I shows that compound 19 is reacted with an acid (e.g., concentrated hydrochloric acid, etc.) in a suitable solvent (e.g., methanol, etc.) at a suitable temperature (e.g., about 50° C.) to obtain compound 20.

[0208] Process 4

[0209] In step A of scheme 4, Buchwald coupling can be carried out in a suitable solvent (e.g., 1,4-dioxane) at a suitable temperature (e.g., about 110° C.) using a suitable catalyst (e.g., Xantphos Pd G2, etc.) and a suitable base (e.g., sodium tert-butoxide) to react compound 8 with compound 20 to give compound 23. Alternatively, compound 8 can also be reacted with tert-butyl carbamate under the aforementioned Buchwald coupling conditions via step B, followed by acid treatment to give compound 21. Step C shows the enantioselective N-alkylation of compound 21 with compound 10 using a chiral metal complex (e.g., CuI and a chiral ligand, etc.) to give compound 22. Step D describes the contact of compound 22 with azide 12 under standard 1,3-dipolar cycloaddition conditions to provide compound 23.

[0210] Process 5

[0211] In step A of scheme 5, compound 24 can be reacted with a suitable benzyl halide (e.g., benzyl bromide, etc.) in a suitable solvent (e.g., toluene, etc.) at about 60° C. in the presence of a suitable base (e.g., silver carbonate, etc.) to produce compound 25. Step B describes the reduction of the nitro group of compound 25 with a suitable reducing agent (e.g., Fe, SnCl2, etc.) to produce compound 26. Step C describes the reaction of compound 26 with diethyl 2-(ethoxymethylene)malonate in a suitable solvent (e.g., ethanol, etc.) at a suitable temperature (e.g., about 85° C.) to produce compound 27. Step D shows the conversion of compound 27 to 28 under thermal cyclization conditions (i.e., about 250° C.) or microwave conditions. Step E describes the reaction of compound 28 with a suitable chlorinating agent (e.g., SOCl2, POCl3, etc.) in the presence of a catalyst (e.g., DMF, etc.) to produce compound 29. Step F describes the reaction of compound 29 with a suitable amine under standard nucleophilic aromatic substitution conditions in the presence of a base (e.g., DIPEA, etc.) at elevated temperature (e.g., about 60° C.) to give compound 30. Step G describes the hydrolysis of compound 30 in a suitable inorganic base (e.g., NaOH, etc.) in a suitable solvent (e.g., THF, HO, etc.) to give compound 31. In step H, an amide coupling can be carried out with compound 31 and ammonium chloride using an organic base (e.g., DIPEA, etc.) and a suitable coupling agent (e.g., HATU, etc.) in a suitable solvent (e.g., DMF, etc.) to give compound 32. Step I shows the conversion of compound 32 to compound 33 under a suitable dehydrating agent (e.g., TFAA, etc.). Step J describes the debenzylation in the presence of a Lewis acid (e.g., BCl3) to give compound 34. Step K describes the reaction of compound 31 with trifluoromethanesulfonic anhydride in a suitable base (e.g., DIPEA, etc.) in a suitable solvent (e.g., DCM, etc.) at about 60° C. to give compound 35.

[0212] Process 6

[0213] In step A of scheme 6, Buchwald coupling can be carried out in a suitable solvent (e.g., 1,4-dioxane) at a suitable temperature (e.g., about 125° C.) using a suitable catalyst (e.g., Xantphos Pd G2, etc.) and a suitable base (e.g., sodium tert-butoxide) to react compound 35 with compound 20 to give compound 38. Alternatively, compound 35 can also be reacted with tert-butyl carbamate under the aforementioned Buchwald coupling conditions via step B, followed by acid treatment to give compound 36. Step C shows the enantioselective N-alkylation of compound 36 with compound 10 using a chiral metal complex (e.g., CuI and a chiral ligand, etc.) to give compound 37. Step D describes the contacting of compound 37 with azide 12 under standard 1,3-dipolar cycloaddition conditions to provide compound 38.

[0214] Process 7

[0215] In Scheme 7, step A describes the reaction of compound 39 with diethyl 2-(ethoxymethylene)malonate in a suitable solvent (e.g., ethanol, etc.) under reflux to give compound 40. Step B shows the conversion of compound 40 to 41 under thermal cyclization conditions (i.e., about 250° C.) or microwave conditions. Step C describes the reaction of compound 41 with a suitable chlorinating agent (e.g., SOCl2, POCl3, etc.) in the presence of a catalyst (e.g., DMF, etc.) to give compound 42. Step D describes the reaction of compound 42 with a suitable amine under standard nucleophilic aromatic substitution conditions in the presence of a base (e.g., DIPEA, etc.) to give compound 43. Step E describes the hydrolysis of compound 43 with a suitable inorganic base (e.g., LiOH, etc.) in a suitable solvent (e.g., THF, H2O, etc.) to give compound 44. In step F, an amide coupling can be performed with compound 44 and ammonium chloride using an organic base (e.g., DIPEA, etc.) and a suitable coupling agent (e.g., HATU, etc.) in a suitable solvent (e.g., DMF, etc.) to give compound 45. Step G shows the conversion of compound 32 to compound 46 under conditions of a suitable dehydrating agent (eg, TFAA, etc.).

[0216] Process 8

[0217] In step A of Scheme 8, Buchwald coupling can be carried out in a suitable solvent (e.g., 1,4-dioxane) at a suitable temperature (e.g., about 125° C.) using a suitable catalyst (e.g., Xantphos Pd G2, etc.) and a suitable base (e.g., sodium tert-butoxide) to react compound 46 with compound 20 to give compound 49. Alternatively, compound 46 can also be reacted with tert-butyl carbamate under the aforementioned Buchwald coupling conditions via step B, followed by acid treatment to give compound 47. Step C shows the enantioselective N-alkylation of compound 47 with compound 10 using a chiral metal complex (e.g., CuI and a chiral ligand, etc.) to give compound 48. Step D describes the contacting of compound 48 with azide 12 under standard 1,3-dipolar cycloaddition conditions to provide compound 49.

[0218] Preparation Example

[0219] Example 1

[0220] Preparation of (S)-6-{{[1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl](2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl}amino}-8-chloro-4-(neopentylamino)cinnoline-3-carbonitrile

[0221] Step 1:

[0222] (Z)-2-[(4-bromo-2-chlorophenyl)diazo]-2-cyanoacetamide (1-2)

[0223] Compound 1-1 (11.91 g, 58.1 mmol) was dissolved in concentrated HCl (58.1 mL, 697.2 mmol, 12 M), and ice water (250 mL) was added with stirring. The temperature was controlled below 0°C and an aqueous solution (250 mL) of NaNO2 (4 g, 58.1 mmol) was slowly added. Stirring was continued at 0°C for 10 minutes, and an aqueous solution (426 mL) of 2-cyanoacetamide (4.89 g, 58.1 mmol) and sodium acetate (19.1 g, 232 mmol) was added, followed by stirring at room temperature overnight and the resulting solid was collected by filtration. The filter cake was washed with water and dried to obtain an orange solid, which was recrystallized in EtOH, filtered, washed with EtOH (50 mL), and dried to obtain compound 1-2 (5.78 g, yield 33%). MS m / z (ESI): 302.9 [M+H] + .

[0224] Step 2:

[0225] 4-Amino-6-bromo-8-chlorocinnoline-3-carboxamide (1-3)

[0226] At room temperature, AlCl₃ (9.36 g, 70.01 mmol) was added to a suspension of 1-2 in chlorobenzene (60 mL). The reaction was stirred at 110°C under nitrogen for 16 hours. The reaction mixture was cooled to room temperature, and a 2M aqueous HCl solution was slowly added dropwise. The reaction mixture was stirred at 100°C for 2 hours. The reaction mixture was cooled, filtered, washed with EtOH and H₂O, and dried to obtain product 1-3 (2.8 g, 53.36% yield). MS m / z (ESI): 302.9 [M+H] + .

[0227] Step 3:

[0228] 6-Bromo-8-chloro-4-hydroxycinnoline-3-carboxylic acid (1-4)

[0229] At room temperature, KOH (9.38 g, 167.22 mmol) was added to a solution of 1-3 (2.8 g, 9.29 mmol) in DMSO / H2O (30 mL / 20 mL). The solution was reacted at 120°C for 2 days, cooled to room temperature, and ice water (300 mL) was added. The pH of the solution was then adjusted to 6-7 with 3M aqueous hydrochloric acid solution, and a solid precipitated, filtered, washed with H2O (2 x 50 mL), and dried. The product 1-4 was then recrystallized from DMSO to give a light brown solid (980 mg, 34.77% yield). MS m / z (ESI): 304.9 [M+H] + .

[0230] Step 4:

[0231] 6-Bromo-4,8-dichlorocinnoline-3-carboxamide (1-5)

[0232] At room temperature, SOCl2 (10 mL) and DMF (0.5 mL) were added to a 100 mL round-bottom flask containing 1-4 (980 mg, 3.23 mmol). The resulting mixture was heated at reflux for 4 hours, then cooled to room temperature, concentrated under reduced pressure, and redissolved in acetone (20 mL). The suspension was cooled to 0°C in an ice bath, and aqueous ammonia (2 mL) was slowly added dropwise. The mixture was stirred at 0°C for another 15 minutes, and the solid was collected by filtration. It was then washed with H2O and acetone in sequence and dried in vacuo to obtain compound 1-5 (70 mg, yield 6.8%) as a black solid. MS m / z (ESI): 321.9 [M+H] + .

[0233] Step 5:

[0234] 6-Bromo-4,8-dichlorocinnoline-3-carbonitrile (1-6)

[0235] At 0°C, POCl3 (10 mL) was slowly added dropwise to 1-5 (70 mg, 0.22 mmol), and the reaction mixture was heated at 100°C for 30 minutes. The mixture was concentrated under reduced pressure, and the residue was suspended in ice water. EA was then added, and the aqueous phase was neutralized with saturated NaHCO3 solution and extracted with EA (2 x 20 mL). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA = 1:1) to afford 1-6 as a solid (50 mg, 75% yield). MS m / z (ESI): 303.9 [M+H] + .

[0236] Step 6:

[0237] 6-Bromo-8-chloro-4-(neopentylamino)cinnoline-3-carbonitrile (1-7)

[0238] At room temperature, 1-6 (50 mg, 0.17 mmol), i-PrOH (5 mL), DIPEA (23.26 mg, 0.18 mmol), and neopentylamine (15 mg, 0.17 mmol) were added to a reactor. The mixture was heated and stirred at 75°C for 5 hours until the reaction was complete. Stirring was then continued in an ice bath for about 1 hour. The solid was filtered and washed twice with glacial i-PrOH (4 mL). The solid was dried to obtain compound 1-7 (15 mg, yield 24.71%). MS m / z (ESI): 354.0 [M+H] + .

[0239] Step 7:

[0240] (S)-6-{{[1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl](2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl}amino}-8-chloro-4-(neopentylamino)cinnoline-3-carbonitrile (1)

[0241] To a solution of 1-7 (88 mg, 0.25 mmol) and 1-8 (73 mg, 0.23 mmol) in dioxane (10 mL) were added XantPhos Pd-G2 (20.19 mg, 0.02 mmol) and sodium tert-butoxide (65.49 mg, 0.68 mmol) at room temperature. The mixture was then heated to 90°C and reacted under nitrogen for 2 hours. The mixture was cooled, concentrated, and purified by preparative HPLC (Waters 2767 / Qda, column model: Atlantis™ T3 prep OBD™™ 19*250 mm and 10 μm; mobile phase A: 0.1% FA / H2O, mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 30% to 45%; retention time: 7.5-9.3 min, total 16 min) to afford compound Y001 (18.40 mg, yield 13.04%). MS m / z(ESI):594.2[M+H] + . 1 HNMR(400MHz,MeOD)δ8.28(d,J=8.0Hz,1H),7.77(s,1H),7.66(d,J=7.1Hz,1H),7.54(s,1H),7.44(t,J=7.9Hz,1H),7.37(d,J=7.7Hz,1H),6.7 9(d,J=7.6Hz,1H),6.54(d,J=14.8Hz,2H),3.68(d,J=13.6Hz,1H),3.56 (s,3H),3.43(d,J=13.6Hz,1H),2.62(s,1H),2.30(s,6H),0.66(s,9H).

[0242] Example 2

[0243] (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carbonitrile

[0244] Step 1:

[0245] 2-(Benzyloxy)-4-chloro-5-nitropyridine (2-2)

[0246] AgCO₃ (4.8 g, 28.65 mmol) was added to a solution of 2-1 (10 g, 57.29 mmol) in toluene (100 mL) under nitrogen protection. Benzyl bromide (10.29 g, 60.16 mmol) was slowly added dropwise at 25°C. After the addition was complete, the temperature was raised to 60°C and the reaction mixture was allowed to react for 16 hours. The temperature was cooled to room temperature, and H₂O (300 mL) was added to the reaction solution. EA (100 mL x 3) was then added for extraction. The organic phases were combined, washed with saturated NaCl solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (EA:PE = 0-10%) to obtain compound 2-2 (5.4 g, yield 35.6%). MS m / z (ESI): 264.9 [M+H] + .

[0247] Step 2:

[0248] 6-(Benzyloxy)-4-chloropyridin-3-amine (2-3)

[0249] 2-2 (5.4 g, 20.40 mmol) and EtOH (60 mL) were added to a reaction flask and stirred. Iron powder (3.4 g, 61.21 mmol) was added, followed by an aqueous solution (15 mL) of NH4Cl (5.46 g, 102 mmol). The temperature was raised to 80°C and the reaction was allowed to react for 3 hours. The mixture was cooled to room temperature and filtered. The filter cake was washed once with EtOH (20 mL), concentrated, and extracted three times with EA (30 mL x 3) after adding H2O (50 mL). The organic phases were combined, washed with saturated brine (20 mL), and concentrated to give compound 2-3 (4.4 g, yield: 91.9%). MS m / z (ESI): 234.9 [M+H] + .

[0250] Step 3:

[0251] Diethyl 2-{[(6-(Benzyloxy)-4-chloropyridin-3-yl)amino]methylene}malonate (2-4)

[0252] Diethyl 2-(ethoxymethylene)malonate (4.86 g, 22.50 mmol) was added to a solution of 2-3 (4.4 g, 18.75 mmol) in EtOH (50 mL) under nitrogen protection. The temperature was raised to 85°C and the reaction was allowed to proceed for 16 hours. The temperature was lowered to 25°C and concentrated under reduced pressure. The crude product was slurried with PE (40 mL) and filtered to obtain compound 2-4 (5.5 g, yield 72.4%). MS m / z (ESI): 404.9 [M+H] + .

[0253] Step 4:

[0254] 6-(Benzyloxy)-8-chloro-4-hydroxy-1,5-naphthyridine-3-carboxylic acid ethyl ester (2-5)

[0255] Compound 2-4 (5.5 g, 13.6 mmol) and diphenyl ether (50 mL) were added to a reaction flask under nitrogen protection and heated to 250°C for 2 hours. The temperature was cooled to room temperature, PE (150 mL) was added, and the mixture was filtered. The crude product was then purified on a silica gel column (PE:EA = 3:1) to obtain compound 2-5 (3.8 g, yield 78%). MS m / z (ESI): 358.9 [M+H] + .

[0256] Step 5:

[0257] 6-(Benzyloxy)-4,8-dichloro-1,5-naphthyridine-3-carboxylic acid ethyl ester (2-6)

[0258] At room temperature, 2-5 (3.8 g, 10.6 mmol) and SOCl2 (30 mL) were added to a reaction flask. Under nitrogen protection, DMF (1 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure, and the crude product was poured into ice water (50 mL). The pH was adjusted to approximately 8 with NaHCO3. The product was extracted with EA (30 mL x 3). The organic phases were combined and washed with saturated brine. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was then purified on silica gel (PE:EA = 3:1) to obtain compound 2-6 (3.2 g, yield 80.2%). MS m / z (ESI): 377.1 [M+H] + .

[0259] Step 6:

[0260] 6-(Benzyloxy)-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carboxylic acid ethyl ester (2-7)

[0261] 2-6 (1.35 g, 3.59 mmol) was dissolved in 1,4-dioxane (20 mL), and DIPEA (1.38 g, 10.9 mmol) and neopentylamine (312 mg, 3.60 mmol) were added sequentially. The mixture was reacted at 60°C under nitrogen atmosphere for 2 hours. The reaction solution was concentrated and passed through a silica gel column (PE:EA = 3:1) to obtain compound 2-7 (1.25 g, yield 81.5%). MS m / z (ESI): 428.1 [M+H] + .

[0262] Step 7:

[0263] 6-(Benzyloxy)-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carboxylic acid (2-8)

[0264] 2-7 (1.25 g, 2.9 mmol) was dissolved in EtOH (20 mL) and H2O (5 mL), and LiOH (130 mg, 5.8 mmol) was added. The mixture was reacted at 40°C for 5 hours. The temperature was lowered to 10°C, and the pH was adjusted to approximately 7 with 1M HCl solution. The mixture was concentrated under reduced pressure to remove EtOH and filtered to obtain compound 2-8 (980 mg, yield 84.7%). MS m / z (ESI): 400.0 [M+H] + Step 8:

[0265] 6-(Benzyloxy)-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carboxamide (2-9)

[0266] 2-8 (980 mg, 2.45 mmol) was dissolved in DMF (10 mL), and HATU (1.4 g, 3.68 mmol) and DIPEA (948 mg, 7.35 mmol) were added. The mixture was stirred at 25°C for 10 minutes. Ammonium chloride (276 mg, 4.9 mmol) was then added and the mixture was allowed to react at 25°C for 2 hours. The reaction was quenched with H2O (30 mL) and filtered to give compound 2-9 (950 mg, 96% yield). MS m / z (ESI): 399.0 [M+H] + .

[0267] Step 9:

[0268] 6-(Benzyloxy)-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carbonitrile (2-10)

[0269] 2-9 (950 mg, 2.38 mmol) was dissolved in anhydrous DCM (15 mL), and DIPEA (920 mg, 7.14 mmol) was added. Under nitrogen protection, the temperature was lowered to 0°C, and TFAA (750 mg, 3.57 mmol) was added dropwise. The reaction was continued at 0°C for 2 hours. Saturated aqueous sodium bicarbonate solution (10 mL) was added, and the layers were separated. The aqueous phase was extracted twice with DCM. The organic phases were combined and washed once with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was passed through a silica gel column (PE:EA = 2:1) to obtain compound 2-10 (810 mg, yield 89%). MS m / z (ESI): 380.0 [M+H] + .

[0270] Step 10:

[0271] 8-Chloro-6-hydroxy-4-(neopentylamino)-1,5-naphthyridine-3-carbonitrile (2-11)

[0272] 2-10 (810 mg, 2.13 mmol) was dissolved in anhydrous DCM (15 mL) under nitrogen protection. The temperature was lowered to -60°C and a dichloromethane solution of boron trichloride (6.39 mL, 1.0 mol / L) was added dropwise. After the addition was complete, the temperature was slowly raised to 0°C and allowed to react for 1 hour. The reaction was quenched by the addition of saturated aqueous ammonium chloride (10 mL). The layers were separated and the aqueous layer was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (PE:EA = 1:1) to afford compound 2-11 (420 mg, 68.0% yield). MS m / z (ESI): 291.1 [M+H] + .

[0273] Step 11:

[0274] 4-Chloro-7-cyano-8-(neopentylamino)-1,5-naphthyridin-2-yl trifluoromethanesulfonate (2-12)

[0275] 2-11 (420 mg, 1.44 mmol) and DIPEA (560 mg, 4.34 mmol) were added to a reaction flask under nitrogen atmosphere. The temperature was cooled to 0°C and Tf2O (609 mg, 2.16 mmol) was added dropwise. After the addition was complete, the reaction was allowed to react at 0°C for 2 hours. The reaction was quenched by the addition of aqueous ammonium chloride (10 mL). The layers were separated and the aqueous layer was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (PE:EA = 3:1) to obtain compound 2-12 (420 mg, yield 69.4%). MS m / z (ESI): 423.0 [M+H] + .

[0276] Step 12:

[0277] (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-(neopentylamino)-1,5-naphthyridine-3-carbonitrile (Y002)

[0278] 1-8 (50 mg, 0.155 mmol), 2-12 (126 mg, 0.30 mmol), XantPhos-Pd-G2 (26 mg, 0.03 mmol), sodium tert-butoxide (43 mg, 0.45 mmol), and anhydrous 1,4-dioxane (10 mL) were added to a single-necked flask. Under nitrogen protection, the temperature was raised to 80°C and the reaction was allowed to proceed for 2.5 hours. The temperature was lowered, the mixture was concentrated under reduced pressure, and the mixture was filtered through a column. The crude product was purified by reverse phase chromatography (NH4OH) to obtain compound Y002 (19.5 mg, yield 21.9%). MS m / z (ESI): 594.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.56(d,J=6.8Hz,1H),8.28(s,1H),8.18(d,J=7.9Hz,1H),8.02(s,1H),7.71(d,J=7.3Hz,1H),7.47(dd,J=7.7,2.8Hz,2H),7. 44(s,1H),7.05(s,1H),6.90(d,J=6.6Hz,1H),6.67(d,J=7.6Hz,1H),3.52- 3.46(m,4H),3.42(d,J=6.1Hz,1H),2.67(s,1H),2.29(s,6H),0.69(s,9H).

[0279] Example 3

[0280] Preparation of (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)-1,7-naphthyridine-3,8-dicarbonitrile

[0281] Step 1:

[0282] (E)-Diethyl 2-{[(2,6-dichloropyridin-3-yl)imino]methyl}malonate (3-2)

[0283] 3-1 (10 g, 6.2 mmol) was dissolved in EtOH (100 mL), and diethyl 2-(ethoxymethylene)malonate (4.86 g, 22.50 mmol) was added. Under nitrogen protection, the temperature was raised to 85°C and the reaction was allowed to proceed for 10 hours. The temperature was lowered to 25°C and concentrated under reduced pressure. The crude product was slurried with PE (40 mL) and filtered to obtain compound 3-2 (18.0 g, yield 87.9%). MS m / z (ESI): 332.9 [M+H] + .

[0284] Step 2:

[0285] 6,8-Dichloro-4-hydroxy-1,7-naphthyridine-3-carboxylic acid ethyl ester (3-3)

[0286] 3-2 (18.0 g, 5.42 mmol) and diphenyl ether (150 mL) were added to a reaction flask under nitrogen atmosphere and heated to 260°C for 1.5 hours. The temperature was cooled to room temperature, PE (150 mL) was added, and the mixture was stirred. A large amount of solid precipitated, which was filtered. The filter cake was slurried with DCM (50 mL) and filtered to obtain a yellow crude product, compound 3-3 (2.8 g, 18% yield), which was used directly in the next step. MS m / z (ESI): 286.9 [M+H] + .

[0287] Step 3:

[0288] 4,6,8-Trichloro-1,7-naphthyridine-3-carboxylic acid ethyl ester (3-4)

[0289] Controlling the temperature at around 10°C, 3-3 (2.8 g, 9.75 mmol) and SOCl2 (30 mL) were added to the reaction flask. Under nitrogen, DMF (1 mL) was slowly added dropwise. After complete addition, the mixture was stirred at room temperature for 12 hours. After concentration, the crude product was poured into ice water (50 mL), and the pH was adjusted to approximately 8 with sodium bicarbonate. The product was extracted with EA (30 mL x 3). The organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified on a silica gel column (PE:EA = 3:1) to afford compound 3-4 (2.2 g, 79.9% yield) as a yellow solid. MS m / z (ESI): 303.9 [M+H] + .

[0290] Step 4:

[0291] 6,8-Dichloro-4-(neopentylamino)-1,7-naphthyridine-3-carboxylic acid ethyl ester (3-5)

[0292] 3-4 (2.2 g, 7.23 mmol) was dissolved in THF (20 mL), and DIPEA (2.80 g, 21.7 mmol) and neopentylamine (629 mg, 7.23 mmol) were added sequentially. The mixture was reacted at 10°C under nitrogen atmosphere for 4 hours. After concentration under reduced pressure, the mixture was purified on a silica gel column (PE:EA = 3:1) to afford compound 3-5 (1.9 g, 74.0% yield) as a yellow solid. MS m / z (ESI): 356.1 [M+H] +

[0293] Step 5:

[0294] 6,8-Dichloro-4-(neopentylamino)-1,7-naphthyridine-3-carboxylic acid (3-6)

[0295] 3-5 (1.9 g, 5.35 mmol) was dissolved in THF / H2O (20 mL / 5 mL), and LiOH (256 mg, 10.7 mmol) was added. The mixture was reacted at 10°C for 10 hours. The pH was adjusted to approximately 7 with 1 M HCl solution, and the mixture was concentrated under reduced pressure and filtered to obtain 3-6 (1.5 g, 80% yield). MS m / z (ESI): 328.1 [M+H] + .

[0296] Step 6:

[0297] 6,8-Dichloro-4-(neopentylamino)-1,7-naphthyridine-3-carboxamide (3-7)

[0298] 3-6 (1.5 g, 4.58 mmol) was dissolved in DMF (20 mL), and HATU (2.6 g, 6.88 mmol) and DIPEA (1.77 g, 13.7 mmol) were added. The mixture was stirred at 25°C for 10 minutes. Ammonium chloride (517 mg, 9.16 mmol) was then added, and the mixture was allowed to react at 25°C for 2 hours. H2O (30 mL) was added to the reaction solution, and the mixture was filtered to obtain compound 3-7 (1.32 g, yield 88%). MS m / z (ESI): 327.0 [M+H] + .

[0299] Step 7:

[0300] 6,8-Dichloro-4-(neopentylamino)-1,7-naphthyridine-3-carbonitrile (3-8)

[0301] 3-7 (1.32 g, 4.04 mmol) was dissolved in anhydrous DCM (15 mL), and DIPEA (1.56 g, 12.12 mmol) was added. Under nitrogen protection, the temperature was lowered to 0°C, and trifluoroacetic anhydride (1.27 g, 6.06 mmol) was added dropwise. The reaction was continued at 0°C for 2 hours. A saturated aqueous sodium bicarbonate solution (10 mL) was added, and the layers were separated. The aqueous layer was extracted twice with DCM, and the organic phases were combined and washed once with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography (PE:EA=2:1) ​​to obtain compound 3-8 (850 mg, yield 68%). MS m / z (ESI): 309.1 [M+H] + .

[0302] Step 8:

[0303] 6-Chloro-4-(neopentylamino)-1,7-naphthyridine-3,8-dicarbonitrile (3-9)

[0304] 3-8 (500 mg, 1.62 mmol) was dissolved in anhydrous 1,4-dioxane (15 mL), and XantPhos-Pd-G2 (140 mg, 0.16 mmol) and Zn(CN)2 (104 mg, 0.89 mmol) were added. Under nitrogen protection, the temperature was raised to 120°C and the reaction was allowed to react for 2 hours. The temperature was lowered, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column (PE:EA=2:1) ​​to obtain compound 3-9 (320 mg, yield 66%). MS m / z (ESI): 300.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.96 (s, 1H), 8.75 (s, 1H), 8.61 (s, 1H), 3.78 (d, J = 6.6Hz, 2H), 1.01 (s, 9H).

[0305] Step 9:

[0306] (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)-1,7-naphthyridine-3,8-dicarbonitrile (Y003)

[0307] 1-8 (80 mg, 0.25 mmol), 3-9 (150 mg, 0.50 mmol), XantPhos-Pd-G2 (44 mg, 0.05 mmol), sodium tert-butoxide (72 mg, 0.75 mmol), and anhydrous 1,4-Dioxane (10 mL) were added to a sealed tube under nitrogen protection. The temperature was raised to 125°C and the reaction was allowed to proceed for 2.5 hours. The temperature was lowered, the mixture was concentrated under reduced pressure, and the mixture was purified by column chromatography. The crude product was purified by reverse phase chromatography (NH4OH) to obtain compound Y003 (46 mg, 31.5% yield). MS m / z (ESI): 585.3 [M+H] + . 1 H NMR (400MHz, MeOD) δ8.33(d,J=7.9Hz,1H),8.25(s,1H),7.82(s,1H),7.75(d,J=7.0Hz,1H),7.49(t,J=7.8Hz,1H),7.41(d,J=7.7Hz,1H ),7.24(s,1H),6.97-6.88(m,2H),3.82(d,J=13.9Hz,1H),3.71(d,J=13.9Hz,1H),3.61(s,3H),2.67(s,1H),2.37(s,6H),0.96(s,9H).

[0308] Example 4

[0309] Preparation of (S)-8-chloro-6-{[(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)cinnoline-3-carbonitrile

[0310] Step 1:

[0311] 5-Formyl-2-methylisoquinolin-2-ium(4-2)

[0312] At room temperature, 4-1 (20 g, 127 mmol) was dissolved in MeCN (120 mL), and CH3I (36 g, 254 mmol) was slowly added. The mixture was stirred at room temperature for 12 hours. After the reaction, the mixture was filtered, and the filter cake was washed with toluene (30 mL x 3) and dried at approximately 30°C to obtain compound 4-2 (34 g, 90% yield). The crude product was used directly in the next reaction without further purification. MS m / z (ESI): 172.2 [M+H] + .

[0313] Step 2:

[0314] 2-Methyl-1-oxo-1,2-dihydroisoquinoline-5-carbaldehyde (4-3)

[0315] 4-2 (34 g, 114 mmol) and potassium ferricyanide (75 g, 228 mmol) were dissolved in H₂O (300 mL). Under nitrogen, a KOH (25.5 g, 456 mmol) aqueous solution (200 mL) was slowly added to the reaction solution, followed by reaction at 5°C for 2 hours. After the reaction, the mixture was filtered and the resulting filter cake was washed with H₂O (100 mL x 3). The crude product was purified by silica gel column chromatography (PE:EA = 1:1) to obtain compound 4-3 (13 g, yield 61.9%). MS m / z (ESI): 188.0 [M+H] + .

[0316] Step 3:

[0317] 1-(2-Methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)prop-2-en-1-yl acetate (4-4)

[0318] 4-3 (4.0 g, 21.4 mmol) was dissolved in THF (120 mL). Ethynylmagnesium bromide (85.6 mL, 42.8 mmol) was slowly added under nitrogen-purging and stirring conditions and the mixture was allowed to react at 0°C for 4 hours. Acetyl chloride (3.4 g, 42.8 mmol) was then added dropwise and allowed to react for 4 hours. After the reaction, the mixture was quenched with saturated aqueous sodium bicarbonate solution (60 mL) and extracted with EA (80 mL x 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA=1:2) to give compound 4-4 (4.3 g, yield 79.6%). MS m / z (ESI): 256.1 [M+H] + .

[0319] Steps 4 and 5:

[0320] Methyl (1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)acetate (4-7)

[0321] At room temperature, 4-5 (1.0 g, 17.5 mmol) was dissolved in acetonitrile (45 mL), DIPEA (2.25 g, 17.5 mmol) was added, and the mixture was stirred for 20 minutes. 1H-imidazole-1-sulfonyl azide hydrochloride (5.98 g, 21.0 mmol) was then added portionwise. The reaction mixture was stirred at room temperature under nitrogen for 10 hours to obtain compound 4-6. The crude product was directly used for the next step. 4-4 (2.0 g, 7.84 mmol), copper sulfate pentahydrate (392 mg, 1.57 mmol), and sodium ascorbate (776 mg, 3.92 mmol) were dissolved in 2-methyltetrahydrofuran (40 mL), and an acetonitrile solution of 4-6 (33 mL, 12.54 mmol) was added. The reaction mixture was reacted at 75°C under nitrogen for 24 hours. After the reaction was complete, H2O (30 mL) was added, and the mixture was extracted with EA (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by normal phase column chromatography (DCM:MeOH = 10:1) to obtain compound 4-7 (1.1 g, yield 41.5%). MS m / z (ESI): 677.1 [2M+H] + .

[0322] Step 6:

[0323] 5-[(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(hydroxy)methyl]-2-methylisoquinolin-1(2H)-one (4-8)

[0324] 4-7 (2.3 g, 6.8 mmol) was dissolved in THF / H2O (30 mL / 5 mL), and NaOH (544 mg, 13.6 mmol) was added. The reaction was allowed to react at room temperature for 12 hours. After the reaction, the pH was adjusted to 6-7 with 1N HCl. The solution was concentrated under reduced pressure to remove most of the THF. The concentrate was extracted with DCM (30 mL x 3). The organic phases were combined, washed with saturated brine (30 mL), dried, filtered, and concentrated. The crude product was purified by normal phase column chromatography (DCM:MeOH = 10:1) to afford compound 4-8 (1.2 g, 60.0% yield). MS m / z (ESI): 297.0 [M+H] + .

[0325] Step 7:

[0326] 5-(1-cyclopropyl-1H-1,2,3-triazole-4-carbonyl)-2-methylisoquinolin-1(2H)-one (4-9)

[0327] 4-8 (1.4 g, 4.73 mmol) was dissolved in DCM (30 mL), and Dess-Martin reagent (4.0 g, 9.46 mmol) was added portionwise and allowed to react at room temperature for 4 hours. After completion, a saturated aqueous sodium bicarbonate solution (30 mL) was added to quench the reaction, and the mixture was extracted with DCM (30 mL x 3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a silica gel column (PE:EA = 1:1) to afford 4-9 (1.1 g, 78% yield). MS m / z (ESI): 295.0 [M+H] + .

[0328] Step 8:

[0329] (R,E)-N-[(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methylene]-2-methylpropane-2-sulfonamide (4-11)

[0330] Compounds 4-9 (1.1 g, 3.7 mmol) and 4-10 (1.34 g, 11.1 mmol) were added to anhydrous toluene (30 mL), followed by tetraethyl titanate (2.53 g, 11.1 mmol). The mixture was reacted at 75°C under nitrogen atmosphere for 16 hours. The reaction mixture was returned to room temperature, concentrated, and purified by silica gel column chromatography (PE:EA = 1:1) to afford compound 4-11 (750 mg, 51% yield). MS m / z (ESI): 398.2 [M+H] + .

[0331] Step 9:

[0332] (S)-N-[(S)-(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]-2-methylpropane-2-sulfonamide (4-12)

[0333] 4-11 (750 mg, 1.89 mmol) was dissolved in anhydrous DCM (20 mL) under nitrogen protection. The temperature was lowered to 0°C, and a solution of lithium tri-sec-butylborohydride (1 mol / L, 3.77 mL, 3.77 mmol) was slowly added dropwise. The reaction was allowed to react at 0°C for 4 hours. Saturated aqueous ammonium chloride was slowly added dropwise to the reaction solution to quench the reaction. The aqueous phase was extracted twice with DCM, and the organic phases were combined and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 4-12 (520 mg, yield 69%). MS m / z (ESI): 400.3 [M+H] + .

[0334] Step 10:

[0335] (S)-5-[Amino(1-cyclopropyl-1H-1,2,3-triazol-4-yl)methyl]-2-methylisoquinolin-1(2H)-one (4-13)

[0336] 4-12 (520 mg, 1.30 mmol) was dissolved in MeOH (5 mL), and HCl (20 mL, 0.1 M) was added. The mixture was allowed to react at 50°C for 24 hours. After completion of the reaction, the reaction mixture was cooled to 10°C, the pH was adjusted to approximately 7, and the mixture was concentrated. The crude product was isolated and purified by column chromatography (DCM:MeOH = 10:1) to obtain compound 4-13 (260 mg, 67% yield). MS m / z (ESI): 591.1 [2M+H] + .

[0337] Step 11:

[0338] (S)-8-Chloro-6-{[(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)cinnoline-3-carbonitrile (Y004)

[0339] At room temperature, 1-7 (60 mg, 0.17 mmol) was dissolved in 1,4-dioxane (10 mL). Under nitrogen, 4-13 (50 mg, 0.17 mmol), XantPhos-Pd-G2 (15.11 mg, 0.02 mmol), and sodium tert-butoxide (49 mg, 0.51 mmol) were added sequentially. The reaction mixture was then heated to 90°C and stirred for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water (10 mL) and extracted with DCM (10 mL x 3). The organic phases were combined and concentrated under reduced pressure. The crude product was purified by HPLC (Waters 2767 / Qda, column model: Atlantis™ T3 prep OBD™ 19*250 mm and 10 μm; mobile phase A: 0.1% FA / H2O, mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 40% to 50%; retention time: 7.7-9.3 min, total 16 min) to obtain compound Y004 (22.28 mg, yield 23%). MS m / z (ESI): 568.2 [M+H] + . 1 H NMR(400MHz,MeOD)δ8.35(d,J=7.9Hz,1H),7.82(s,1H),7.74(d,J=7.3Hz,1H),7.61(d ,J=2.2Hz,1H),7.51(t,J=7.8Hz,1H),7.44(d,J=7.6Hz,1H),6.86(d,J=7.7Hz,1H),6.6 2(d,J=2.2Hz,1H),6.57(s,1H),3.92-3.84(m,1H),3.74(d,J=13.6Hz,1H),3.64(d,J= 6.9Hz,3H),3.51(d,J=13.7Hz,1H),1.21-1.18(m,2H),1.18-1.13(m,2H),0.75(s,9H).

[0340] Example 5

[0341] Preparation of (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)cinnoline-3,8-dicarbonitrile

[0342] Step 1:

[0343] Compound 1 (30 mg, 0.05 mmol), zinc powder (0.65 mg, 0.01 mmol), Pd(dppf)Cl2 (1.83 mg, 0.002 mmol), and Zn(CN)2 (7.11 mg, 0.06 mmol) were dissolved in DMA (10 mL) at room temperature and purged with nitrogen for 2 minutes. The mixture was heated to 200°C in a microwave reactor for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with H2O (10 mL) and extracted with DCM (10 mL x 3). The organic phases were combined and concentrated under reduced pressure. The crude product was separated and purified by preparative HPLC (Waters 2767 / Qda, column model: Atlantis™ T3 prep OBD™ 19*250 mm and 10 μm; mobile phase A: 0.1% FA / H2O, mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 31% to 42%; retention time: 6.0-8.5 min, total 16 min) to obtain compound Y005 (7.94 mg, yield 27.15%). MS m / z (ESI): 585.3 [M+H] + .

[0344] 1 H NMR (400MHz, DMSO-d6) δ8.20 (d, J=7.6Hz, 1H), 8.18-8.12 (m, 1H), 8.01 (s, 1H), 7.9 6(d,J=2.1Hz,1H),7.64(d,J=7.2Hz,1H),7.51(d,J=7.7Hz,1H),7.44(t,J=7.8Hz, 1H),7.27(s,1H),7.17(s,1H),6.71(d,J=7.7Hz,1H),6.63(d,J=6.8Hz,1H),3.67( dd,J=13.9,7.7Hz,1H),3.52-3.45(m,4H),2.67(s,1H),2.29(s,6H),0.71(s,9H).

[0345] Example 6

[0346] Preparation of (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)-1,5-naphthyridine-3,8-dicarbonitrile

[0347] Step 1:

[0348] Compound Y002 (90 mg, 0.15 mmol) and Zn(CN)2 (70 mg, 0.6 mmol) were dissolved in 1,4-dioxane (5 mL) at room temperature. XantPhos-Pd-G2 (13 mg, 0.015 mmol) was added, and the mixture was heated to 120°C and stirred for 3 hours under nitrogen. The reaction solution was concentrated under reduced pressure and purified by preparative HPLC (Waters 2767 / Qda, column model: XBridge XBridge C18, 19*250 mm, 10 μm; mobile phase A: 0.05% NH3H2O / H2O, mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 40%-50%; retention time: 8.1-8.9 min, total 16 min) to obtain compound Y006 (49.37 mg, yield 67.7%). MS m / z(ESI):585.3[M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.86(d,J=6.5Hz,1H),8.32(s,1H),8.19(d,J=7.8Hz,1H),8.03(s,1H),7.75-7.69(m,2H),7.50-7.44(m,2H ),7.05(s,1H),6.93(d,J=6.4Hz,1H),6.69(d,J=7.6Hz,1H),3.49(s,3H),3.44-3.36(m,2H),2.67(s,1H),2.29(s,6H),0.68(s,9H).

[0349] Example 7

[0350] Preparation of (S)-6-{[(1-cyclopropyl-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-(neopentylamino)cinnoline-3,8-dicarbonitrile

[0351] Step 1:

[0352] Compound Y004 (40 mg, 0.07 mmol), zinc powder (0.92 mg, 0.01 mmol), Pd(dppf)Cl2 (25.76 mg, 0.04 mmol), and Zn(CN)2 (9.92 mg, 0.08 mmol) were dissolved in DMA (10 mL) at room temperature and purged with nitrogen for 2 minutes. The reaction mixture was heated to 200°C in a microwave reactor for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with H2O (10 mL) and extracted with DCM (10 mL x 3). The organic phases were combined, concentrated under reduced pressure, and then purified by preparative HPLC (Waters 2767 / Qda, column model: Atlantis™ T3 prep OBD™ 19*250 mm and 10 μm; mobile phase A: 0.1% NH4HCO3 / H2O, mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 34% to 45%; retention time: 8.0 to 10.3 min, total 16 min) to obtain compound Y007 (1.01 mg, yield 2.58%). MS m / z (ESI): 559.2 [M+H] + .

[0353] 1 H NMR(400MHz,DMSO-d6)δ8.20(d,J=8.1Hz,1H),8.13(d,J=6.8Hz,1H),8.00(s,1H ),7.97(s,1H),7.64(d,J=6.9Hz,1H),7.51(d,J=7.5Hz,1H),7.44(t,J=7.7Hz,1 H),7.28(s,1H),7.19(s,1H),6.71(d,J=7.4Hz,1H),6.59(d,J=7.0Hz,1H),3.93 (s,1H),3.65(s,1H),3.52(s,1H),3.49(s,3H),1.14-1.04(m,4H),0.72(s,9H).

[0354] Example 8

[0355] Preparation of 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-{[(R)-3,3-dimethyltetrahydro-2H-pyran-4-yl]amino}cinnoline-3-carbonitrile and 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-{[(R)-3,3-dimethyltetrahydro-2H-pyran-4-yl]amino}cinnoline-3-carbonitrile

[0356] Step 1:

[0357] 6-Bromo-8-chloro-4-[(3,3-dimethyltetrahydro-2H-pyran-4-yl)amino]cinnoline-3-carbonitrile (8-2)

[0358] 1-6 (320 mg, 1.06 mmol), 8-1 (136 mg, 1.06 mmol) and DIPEA (410 mg, 3.18 mmol) were dissolved in DMF (10 mL). The reaction solution was heated to 90°C and stirred under nitrogen overnight. After cooling to room temperature, H2O (30 mL) was added to dilute the mixture and extracted with EA (20 mL x 3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (PE:EA=1:1) to give compound 8-2 (350 mg, yield 83.7%). MS m / z (ESI): 395.0 [M+H] + .

[0359] Step 2:

[0360] 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-{[(R)-3,3-dimethyltetrahydro-2H-pyran-4-yl]amino}cinnoline-3-carbonitrile and 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-{[(R)-3,3-dimethyltetrahydro-2H-pyran-4-yl]amino}cinnoline-3-carbonitrile

[0361] Compound 8-2 (350 mg, 0.89 mmol), 1-8 (286 mg, 0.89 mmol), XantPhos-Pd-G2 (80 mg, 0.09 mmol), and sodium tert-butoxide (170 mg, 1.78 mmol) were dissolved in anhydrous 1,4-dioxane (10 mL). The reaction mixture was heated to 120°C and stirred for 3 hours under nitrogen. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (DCM:MeOH = 10:1) to obtain the crude product. The crude product was then purified by prep-HPLC (column model: XBridge@Prep C18 5um 19*150mm; mobile phase A: 0.1% FA / H2O, mobile phase B: MeCN; gradient: 0-95%; retention time: 4.5-9.3 min, flow rate: 17 mL / min, total 16 min). Compound Y008a (50 mg, yield 8.8%) and compound Y008b (60 mg, yield 10.6%) were obtained. 8a: MS m / z (ESI): 636.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.16(d,J=7.9Hz,1H),8.11(d,J=6.7Hz,1H),7.96(s,1H),7.74(dd,J=7.5,4.8 Hz,2H),7.50(d,J=7.7Hz,1H),7.41(t,J=7.8Hz,1H),6.74(d,J=7.7Hz,1H),6.65(d,J=7.1Hz,2H),6.3 6(d,J=10.4Hz,1H),4.09(d,J=5.6Hz,1H),3.93(d,J=11.5Hz,1H),3.49(s,3H),3.26(d,J=11.5Hz,2H) ,2.96(d,J=11.5Hz,1H),2.67(s,1H),2.30(s,6H),1.82-1.70(m,2H),0.44(s,3H),0.22(s,3H).8b:MS m / z(ESI):636.1[M+H] + , 1H NMR (400MHz, DMSO-d6) δ8.26(d,J=7.8Hz,1H),8.04(s,1H),7.91(d,J=6.9Hz,1H),7.64(s,1H),7.58 (d,J=7.7Hz,1H),7.52-7.42(m,2H),6.95(s,1H),6.69(t,J=7.5Hz,2H),6.31(d,J=10.0Hz,1H),4.2 4(d,J=8.1Hz,1H),3.91(d,J=11.2Hz,1H),3.52(s,3H),3.43(d,J=11.4Hz,1H),3.17(d,J=5.2Hz,1H ),3.07(d,J=11.5Hz,1H),2.66(s,1H),2.29(s,6H),1.76(d,J=6.9Hz,2H),0.84(s,3H),0.57(s,3H).

[0362] Example 9

[0363] Preparation of 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-{[(R)-3,3-dimethyltetrahydro-2H-pyran-4-yl)amino]cinnoline-3,8-dicarbonitrile and 6-{[(S)-(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-4-{[(S)-3,3-dimethyltetrahydro-2H-pyran-4-yl)amino]cinnoline-3,8-dicarbonitrile

[0364] Step 1:

[0365] Compound Y008a (54 mg, 0.08 mmol), Zn(CN)2 (12 mg, 0.1 mmol), zinc powder (1 mg, 0.016 mmol), and Pd(dppf)Cl2 (6 mg, 0.008 mmol) were dissolved in DMF (5 mL). The reaction mixture was heated to 200°C under nitrogen and microwave-heated for 1 hour. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated. The crude product was purified by prep-HPLC (column model: XBridge@Prep C185um 19*150mm; mobile phase A: 0.1% TFA / H2O, mobile phase B: MeCN; gradient: 30-55%; retention time: 3.5-7.5 min; flow rate: 17 mL / min, total 16 min) to obtain compound Y009a (10.6 mg, yield 20.8%). MS m / z (ESI): 627.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.27(d,J=6.8Hz,1H),8.16(d,J=7.9Hz,1H),8.05(d,J=1.9Hz,1H),7.96(s,1H),7.7 5(d,J=7.4Hz,1H),7.49(d,J=7.7Hz,1H),7.40(t,J=7.8Hz,1H),6.95(s,1H),6.74(d,J=7.7Hz,1H),6.67(d,J =6.7Hz,1H),6.58(d,J=10.4Hz,1H),4.13(dd,J=15.3,10.4Hz,1H),3.93(d,J=10.7Hz,1H),3.49(s,3H),3.2 6(s,2H),2.97(d,J=11.7Hz,1H),2.67(s,1H),2.30(s,6H),1.77(d,J=13.8Hz,2H),0.46(s,3H),0.24(s,3H).

[0366] Compound Y008b (45 mg, 0.07 mmol), Zn(CN)2 (10 mg, 0.085 mmol), zinc powder (1 mg, 0.014 mmol), and Pd(dppf)Cl2 (5 mg, 0.007 mol) were dissolved in N,N-dimethylacetamide (5 mL). The reaction mixture was heated to 200°C under nitrogen and microwave-heated for 1 hour. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated. The crude product was purified by prep-HPLC (column model: XBridge@Prep C18 5um 19*150mm; mobile phase A: 0.1% TFA / H2O, mobile phase B: MeCN; gradient: 30-60%; retention time: 4.0-7.5 min; flow rate: 17 mL / min, 16 min total) to obtain compound Y009b (18.38 mg, 37.8% yield). MS m / z(ESI):627.2[M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.27(d,J=7.9Hz,1H),8.08(d,J=6.8Hz,1H),8.05(s,1H),7.95(d,J=2.1Hz, 1H),7.58(d,J=7.7Hz,1H),7.50(t,J=7.7Hz,1H),7.44(d,J=7.4Hz,1H),7.24(s,1H),6.68(d,J=7.7H z,2H),6.56(d,J=10.1Hz,1H),4.32-4.25(m,1H),3.93(d,J=11.0Hz,1H),3.52(s,3H),3.45(s,1H),3 .42(s,1H),3.08(d,J=11.6Hz,1H),2.66(s,1H),2.29(s,6H),1.80(s,2H),0.85(s,3H),0.58(s,3H).

[0367] Examples 10-25

[0368] The synthetic routes of compounds numbered Y010-Y025 refer specifically to the synthetic route of Example 3, except that the substituents of the intermediates are slightly different and are determined according to the target compound.

[0369] Comparative Example 1

[0370] The structure of compound (S)-6-{[(1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]amino}-8-chloro-4-(neopentylamino)quinoline-3-carbonitrile is:

[0371] The synthetic route of the compound of Comparative Example 1 refers to the synthetic route of the compound with specification number 713 in International Patent No. WO2017 / 007689.

[0372] Biological test data

[0373] Test Example 1: High-throughput Cot biochemical assay

[0374] Human Cot enzyme activity was measured using PhosphoSens (AssayQuant) (based on the chelation enhanced fluorescence (ChEF) principle). In this assay, Cot catalyzes the phosphorylation of a peptide substrate containing an 8-hydroxyquinoline derivative side chain. After the peptide substrate is phosphorylated, the phosphate group is chelated with the 8-hydroxyquinoline side chain near the phosphorylation site by a magnesium ion, and the chelated state can be detected by fluorescence. Purified recombinant human Cot catalytic domain (30-397 amino acids) was purchased from Carna Biosciences. Compounds dissolved in DMSO were delivered to Proxi white low-capacity 384-well plates at the desired concentration using an Echo 650 acoustic liquid dispenser. 5uL of Cot enzyme dissolved in reaction buffer was transferred to the assay plate. The reaction buffer was 50 mM HEPES, pH 7.5, 0.01% Brij-35, 10 mM MgCl2, 1.2 mM DTT, 0.5 mM EGTA, 50 uM ATP, and 0.2 mg / mL BSA. After incubation at room temperature for 15 minutes, 5 μL of the peptide substrate dissolved in the reaction buffer was added. The Ensight reader (PerkinElmer) was then used with excitation at 485 nm and emission at 535 nm to read the values. The percentage of inhibition was calculated as follows:

[0375] % inhibition = (maximum signal - compound signal) / (maximum signal - minimum signal) × 100

[0376] “+++” represents IC 50 <10nM, “++” represents IC 50 ≥10nM and IC 50 ≤100nM, “+” represents IC 50 >100nM.

[0377] The results are shown in Table 1:

[0378] Table 1 Inhibition results of the compounds of the present invention on Cot

[0379] The experimental results in Table 1 above indicate that the compounds disclosed in the present invention are effective inhibitors of Osaka thyroid carcinoma (Cot) kinase.

[0380] Among them, the compound with X3 being N has unexpectedly better inhibitory activity, Cot IC 50 Very low (IC of some compounds 50 ≤1nM).

[0381] Test Example 2: Cot monocyte TNFα cell-based assay

[0382] Cryopreserved human monocytes (TPCS) were thawed and diluted to 0.125X10^6 cells / mL in RPMI medium containing Glutamax (10mM HEPES, 1X Pen-Strep, 55μM β-mercaptoethanol, 1mM sodium pyruvate) containing 10% FBS and recovered at 37°C for 2 hours. The cell suspension was then plated on a black 384-well transparent bottom plate (Corning) at a density of 5000 cells / well. The plate was pre-spotted with the test compound and serially diluted in DMSO with a final DMSO concentration of 0.1%. The plated cells were treated with the compound at 37°C for 1 hour. The cells were then stimulated with 50pg / mL of LPS (Sigma), excluding the outer row of the plate for unstimulated cell control wells. The cells were incubated at 37°C for another 4 hours, and then the cells were centrifuged to take 15uL of cell supernatant and analyzed for TNFα content using the ELISA human TNFα detection system (R&D).

[0383] “+++” represents IC 50 <10nM, “++” represents IC 50 ≥10nM and IC 50 ≤100nM, “+” represents IC 50 >100nM. The results are shown in Table 2:

[0384] Table 2 Test results of the compounds of the present invention inhibiting the expression of TNF-α in human PBMC stimulated by LPS

[0385] As shown in Table 2, the exemplary compounds of the present invention have significant inhibitory activity on TNFa production downstream of Osaka thyroid carcinoma (Cot) kinase, which suggests that the compounds of the present invention can be used to treat Cot-related diseases such as inflammation.

[0386] Test Example 3: Pharmacokinetic Evaluation in Mice

[0387] The in vivo pharmacokinetic properties of the compounds were tested using CD-1 (ICR) mice (male, 6-8 weeks old, weighing 32-42 g, Vital River, Beijing) as follows:

[0388] The pharmacokinetic profiles of the compounds following intravenous and oral administration in rodents were tested using standard protocols. Candidate compounds were formulated as clear solutions and administered to mice as single intravenous (IV) and oral (PO) injections. The vehicle consisted of 5% DMSO + 10% Solutol + 85% ddH2O. Oral administration groups fasted overnight (10-14 hours) prior to dosing. Whole blood samples were collected within 24 hours of dosing (0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours for oral administration; 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours for intravenous administration). Blood samples were collected from the submandibular vein or other appropriate means. Approximately 30 μL of blood was collected at each time point, anticoagulated with K2-EDTA, and kept on ice until centrifugation. Blood samples were centrifuged at 4°C at 6800g for 6 minutes to obtain plasma. Plasma was stored at -80°C prior to measuring blood drug concentrations. LC-MS / MS was used to quantitatively analyze the blood drug concentration and calculate the pharmacokinetic parameters, such as peak concentration (C max ), distribution volume (Vd ss ) clearance (CI), half-life (T 1 / 2 ), area under the drug-time curve (AUC 0-last ), bioavailability (F), etc. The test results are shown in Table 4.

[0389] Table 4 Pharmacokinetic data of the compounds of the present invention

[0390] From the experimental results in Table 4, it can be seen that the mouse PK of the Y003 compound of the present invention has a longer half-life and higher oral bioavailability than that of the compound of Comparative Example 1.

[0391] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substituted product thereof, in X 1 N or CR 15 ; X 2 and X 3 are independently N or CH; Where X 1 , X 2 and X 3 At least one is N; R 1 For hydrogen, -OR 7 、-N(R 8 )(R 9 )、-C(O)-R 7 、-S(O)2-R 7 , C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 3-10 The heterocyclic, aryl or heteroaryl groups may be optionally substituted with 1 to 4 Z 1 ; R 2 is hydrogen, -C(O)-R 7 、-C(O)OR 7 、-C(O)N(R 7 2. C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl may be optionally substituted with 1 to 4 Z 2 ; or R 1 and R 2 Together with the nitrogen to which they are attached, they form a heterocyclic or heteroaryl group, wherein each heterocyclic or heteroaryl group is optionally substituted with 1 to 4 Z 2 ; R 3 is ethynyl, heterocyclic or heteroaryl, wherein each ethynyl, heterocyclic or heteroaryl group optionally has 1 to 4 Z 3 ; R 4 is a heterocyclic group, an aryl group or a heteroaryl group, wherein the heterocyclic group, the aryl group or the heteroaryl group is optionally substituted with 1 to 4 Z 4 ; R 5 For hydrogen, halogen, -CN, -NO2, -OR 7 、-N(R 8 )(R 9 )、-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2. -C(O)R 7 、-OC(O)-R 7 、-C(O)OR 7 、-OC(O)OR 7 、-OC(O)N(R 10 )(R 11 )、-C(O)N(R 7 )2、-N(R 7 )C(O)(R 7 ), C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl and heteroaryl may be optionally substituted with 1 to 4 Z 5 ; R 6 is hydrogen, -C(O)-R 7 、-C(O)OR 7 、-C(O)N(R 7 2. C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 3-10 The heterocyclic, aryl or heteroaryl groups may be optionally substituted with 1 to 4 Z 6 ; Each R 7 are independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl, or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl and heteroaryl may be optionally substituted with 1 to 4 Z 7 ; R 8 and R 9 is independently hydrogen at each occurrence, -S(O)2-R 10 、-C(O)-R 10 、-C(O)OR 10 、-C(O)N(R 10 )(R 11) , C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 8 ; R 10 and R 11 is independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted with 1 to 4 Z 9 ; Every Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 and Z 9 are independently hydrogen, oxo, halogen, -NO2, -N3, -CN, thio, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-8 Haloalkyl, C 3-15 Cycloalkyl, heterocyclyl, aryl or heteroaryl, -OR 12 、-C(O)R 12 、-C(O)OR 12 、-C(O)N(R 13 )(R 14 )、-N(R 13 )(R 14 )、-N(R 13 )2(R 14 ) + 、-N(R 12 )C(O)-R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 13 )(R 14 )、-N(R 12 )S(O)2(R 12 ),-NR 12 S(O)2N(R 13 )(R 14 ),-NR 12 S(O)2O(R 12 )、-OC(O)R 12 、-OC(O)-N(R 13 )(R 14 )、-P(O)(OR 12 )2.-OP(O)(OR 12 )2、-CH2P(O)(OR 12 )2、-OCH2P(O)(OR 12 )2、-C(O)OCH2P(O)(OR 12 )2、-P(O)(R 12 )(OR 12 )、-OP(O)(R 12 )(OR 12 )、-CH2P(O)(R 12 )(OR 12 )、-OCH2P(O)(R 12 )(OR 12 )、-C(O)OCH2P(O)(R 12 )(OR 12 )、-P(O)(N(R 12 )2)2、-OP(O)(N(R 12 )2)2、-CH2P(O)(N(R 12 )2)2、-OCH2P(O)(N(R 12 )2)2、-C(O)OCH2P(O)(N(R 12 )2)2、-P(O)(N(R 12 )2)(OR 12 )、-OP(O)(N(R 12 )2)(OR 12 )、-CH2P(O)(N(R 12 )2)(OR 12 )、-OCH2P(O)(N(R 12 )2)(OR 12 )、-C(O)OCH2P(O)(N(R 12 )2)(OR 12 )、-P(O)(R 12 )(N(R 12 )2)、-OP(O)(R 12 )(N(R 12 )2)、-CH2P(O)(R 12 )(N(R 12 )2)、-OCH2P(O)(R 12 )(N(R 12 )2)、-C(O)OCH2P(O)(R 12 )(N(R 12 )2)-SR 12 、-S(O)R 12 、-S(O)(NH)R 12 、-S(O)2R 12 Or -S(O)2N(R 13 )(R 14 ); wherein any alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, aryl, heteroaryl or heterocyclic radical is optionally selected from oxo, halogen, thio, hydroxyl, -NO2, -CN, -N3, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 1-9 Alkoxy, C 1-9 Alkyl hydroxyl, amino, C 1-9 Alkylamino, (C 1-9 Alkyl)2amino, C 1-8 Haloalkyl, C 1-9 Alkylcarbonyl, C 1-9 Alkylamide, C 1-9 substituted by 1 to 4 substituents selected from alkylsulfonyl, aryl, heteroaryl, and heterocyclic groups; Each R 12 are independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclic group, or heteroaryl group, wherein any alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclic group optionally has 1 to 4 Z 7 Group; R 13 and R 14 Each occurrence is independently hydrogen, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, aryl or heteroaryl; any alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclic group optionally has 1 to 4 Z 8 group; or R 13 and R 14 Together with the nitrogen to which they are attached, they form a heterocyclic group, wherein the heterocyclic group is optionally substituted with 1 to 4 Z 8 Group; Each R 15 are independently halogen, -CN, -NO2, -OR 7 、-N(R 8 )(R 9 )、-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2. -C(O)R 7 、-OC(O)-R 7 、-C(O)OR 7 、-OC(O)OR 7 、-OC(O)N(R 10 )(R 11 )、-C(O)N(R 7 )2、-N(R 7 )C(O)(R 7 ), C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-9 Alkylthio, C 1-6 Haloalkyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl; m is 0, 1 or 2.

2. The compound according to claim 1, characterized in that R 1 Select from the following group:

3. The compound according to claim 1, characterized in that The compound has a structure shown in Formula II: Where X 1 , X 2 , X 3 , R 1 , R 3 , R 4 , R 5 and R 6 As defined in claim 1.

4. The compound according to claim 1, characterized in that The compound has a structure shown in formula III-1, III-2 or III-3: Among them, each R 1 , R 3 , R 4 , R 5 and R 6 Independently as defined in claim 1.

5. The compound according to claim 1, characterized in that R 5 Selected from hydrogen, halogen, -CN, -OR 7 、-S(O)-R 7 、-S(O)2R 7 、-S(O)2N(R 7 )2. -C(O)R 7 、-C(O)N(R 7 2. C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl; wherein each C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, aryl, heterocyclyl or heteroaryl may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -OR 12 , C 1-9 Alkyl and aryl.

6. The compound according to claim 1, characterized in that The compound has a structure shown in Formula IV-1, IV-2 or IV-3: Among them, each Z 3 , R 1 , R 4 , R 5 and R 6 Independently as defined in claim 1.

7. [Corrected 24.06.2024 in accordance with Rule 26] The compound according to claim 6, characterized in that Z 3 C 1-9 Alkyl, C 3-15 Cycloalkyl and heterocyclic groups; any C 1-9 Alkyl, C 3-15 Cycloalkyl and heterocyclyl are optionally selected from hydrogen, oxo, halogen, thio, hydroxy, -NO2, -CN, -N3, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, C 1-9 Alkoxy, C 1-9 Alkyl hydroxyl, amino, C 1-9 Alkylamino, (C 1-9 Alkyl)2amino, C 1-9 Haloalkyl, C 1-9 Alkylcarbonyl, C 1-9 Alkylamide, C 1-9 The alkylsulfonyl group is substituted by 1 to 4 substituents selected from the group consisting of alkylsulfonyl, aryl, heteroaryl and heterocyclic groups.

8. [Corrected 24.06.2024 in accordance with Rule 26] The compound according to claim 1, characterized in that Z 3 Selected from 9. The compound according to claim 1, characterized in that R 3 Selected from 10. The compound according to claim 1, characterized in that R 4 Selected from 11. The compound according to claim 1, characterized in that The compound is selected from:

12. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitution thereof, and a pharmaceutically acceptable carrier.

13. Use of the compound according to claim 1, or a pharmaceutically acceptable salt, tautomer, stereoisomer, stereoisomer mixture or isotope substitution thereof, or the pharmaceutical composition according to claim 2 in the preparation of a medicament for preventing or treating a disease or condition mediated by Osaka thyroid carcinoma (Cot) kinase.

14. The use according to claim 11, characterized in that The disease or condition is selected from the group consisting of cancer, diabetes, and inflammatory diseases.

15. An intermediate compound represented by formula M1: in, R 16 is Cl, Br, I or OTf; And X 1 , X 2 , X 3 , R 1 , R 2 , R 5 and R 15 As defined in claim 1.

Citation Information

Patent Citations

  • COT modulators and methods of use thereof

    CN107922390A

  • 6-amino-quinoline-3-carbonitrils as cot modulators

    CN108026067A

  • Cot modulators and methods of use thereof

    CN114026104A

  • Compounds for treating NASH and nafld

    WO2022256529A1